fenfluramine has been researched along with Obesity in 541 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We tested whether 14 wk of dexfenfluramine (30 mg) or fluoxetine (40 mg) treatment would prevent weight gain after subjects quit smoking." | 9.08 | Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. ( el-Khoury, A; Goldberg, H; McDermott, J; Pingitore, R; Spring, B; Wurtman, J; Wurtman, R, 1995) |
| "The results of this study support the longer term use of dexfenfluramine therapy for patients with chronic obesity." | 9.08 | Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. ( Caterson, ID; O'Connor, HT; Richman, RM; Steinbeck, KS, 1995) |
| "To investigate whether a serotoninergic drug such as dexfenfluramine (dF) may have some beneficial effects on energy expenditure (EE) during therapeutic weight reduction, a 3-month study was conducted in a double-blind, placebo-controlled trial." | 9.08 | Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction. ( De Leeuw, IH; Steijaert, MC; Van Gaal, LF; Vansant, GA, 1995) |
| "The effect of the serotonergic agent dexfenfluramine on weight loss, blood pressure, insulin sensitivity and serum lipid levels was determined in a 3-month randomised, double-blind, placebo controlled parallel design study in 50 obese subjects (body mass index 30-44 kg/m2)." | 9.08 | Effect of dexfenfluramine on body weight, blood pressure, insulin resistance and serum cholesterol in obese individuals. ( Gamble, G; Holdaway, IM; Wallace, E; Westbrooke, L, 1995) |
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 9.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| "Dexfenfluramine lowers body weight in obese patients with upper and lower body obesity and reduces the cardiovascular risk factors clustering in upper body obesity." | 9.08 | The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity. ( Adler, G; Ditschuneit, HH; Flechtner-Mors, M, 1996) |
| "The value of a one year prescription of dexfenfluramine (dF) was demonstrated by a large multicentric study performed in centres specialised in the treatment of obesity (Guy-Grand 1989)." | 9.08 | [Tolerance and acceptability of dexfenfluramine in the long-term treatment of obesity in private practice. ESIM Group]. ( Héraïef, E, 1997) |
| "To identify parameters predictive of weight loss during treatment with d-fenfluramine." | 9.08 | Predictors of weight loss during treatment with d-fenfluramine. ( Hopman, E; Meinders, AE; Pijl, H; Toornvliet, AC; Westendorp, RG, 1997) |
| "We conclude that women with abdominal obesity have hyperreactivity of the HPA axis to opiod blockage and that dexfenfluramine treatment reduces this hyperactivity." | 9.08 | Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine. ( Boushaki, FZ; Rasio, E; Serri, O, 1997) |
| "The aim of this work was to investigate the long-term changes of body weight and cardiovascular risk factors after weight reduction with dexfenfluramine (dF) compared to placebo (pI) and additional group therapy." | 9.07 | Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. ( Blomberg, I; Luft, D; Pfohl, M; Schmülling, RM, 1994) |
| "In previous separate studies, dexfenfluramine (DF) and ephedrine/caffeine (EC) have been shown to promote weight loss in obese patients as compared with placebo." | 9.07 | Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. ( Ahlstrøm, F; Breum, L; Frimodt-Møller, J; Pedersen, JK, 1994) |
| "The purpose of this study was to determine the effects of dexfenfluramine on body weight and post-prandial thermogenesis in obese subjects." | 9.07 | Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study. ( Lafreniere, F; Lambert, J; Rasio, E; Serri, O, 1993) |
| "To evaluate the change in lipids and insulin sensitivity in 10 obese type II diabetic patients after treatment with benfluorex or placebo for 2 wk." | 9.07 | Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| " Pharmacological treatment of obesity has evolved in recent years with the development and licensing of potent serotonin agonists, such as dexfenfluramine (D-F)." | 9.07 | Body weight evolution during dexfenfluramine treatment after initial weight control. ( Finer, N, 1992) |
| "A prospective, randomised case-control trial of an anorectic drug, fenfluramine was conducted on 30 patients of simple obesity." | 9.07 | Effect of fenfluramine on serum T3, T4 and TSH levels in obesity. ( Agrawal, JK; Bajpai, HS; Bhatt, RP; Gupta, SS; Singh, SK, 1992) |
| "The effect of dexfenfluramine (dF) on body weight, blood pressure and noradrenergic activity were studied in 30 obese hypertensive patients randomly divided into two groups and treated for 3 months either with dF (30 mg daily; 16 subjects) or placebo (Pl; 14 subjects)." | 9.07 | Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients. ( Detry, JM; Kolanowski, J; Vanbutsele, R; Younis, LT, 1992) |
| "Directly measured food intake in 31 overweight female smokers to test whether (a) calorie and carbohydrate intakes increase after smoking cessation and (b) double-blind d-fenfluramine (30 mg), a serotonin-releasing drug, suppresses weight gain, overeating, and dysphoric mood associated with stopping smoking." | 9.07 | Weight gain and withdrawal symptoms after smoking cessation: a preventive intervention using d-fenfluramine. ( Gleason, R; Kessler, K; Spring, B; Wurtman, J; Wurtman, R, 1991) |
| "Measurements of subjective feeling in 20 patients receiving fenfluramine alternating with placebo and in 19 patients receiving phentermine alternating with placebo indicated that depression of mood occurred four days after fenfluramine withdrawal but no such depression was seen with phentermine." | 9.03 | Withdrawal depression in obese patients after fenfluramine treatment. ( Briggs, M; Steel, JM, 1972) |
| "Sibutramine (BTS 54 524; N-[1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-N,N-dimethylamine hydrochloride monohydrate) is a novel 5-HT (serotonin) and noradrenaline reuptake inhibitor (SNRI) anti-obesity drug." | 8.80 | Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. ( Aspley, S; Cheetham, SC; Heal, DJ; Jackson, HC; Martin, KF; Prow, MR, 1998) |
| " This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpropanolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets." | 8.80 | Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. ( Ryan, DH, 2000) |
| "To assess the validity of the perceptions that appetite-suppressant drugs are ineffective, potentially addictive, and fraught with side effects, we reviewed the effectiveness and safety of two such drugs with purported low abuse potential in the treatment of obesity: mazindol and fenfluramine hydrochloride." | 8.78 | An overview of the efficacy and safety of fenfluramine and mazindol in the treatment of obesity. ( Imperiale, TF; Stahl, KA, 1993) |
| "Fenfluramine has been used for a number of years as a short-term adjunct to diet in the management of obesity." | 8.75 | Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. ( Avery, GS; Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM, 1975) |
| "Dexfenfluramine was better tolerated than ephedrine/caffeine and fluoxetine in short term studies." | 7.78 | Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. ( Davis, R; Faulds, D, 1996) |
| "In the late 1960s, an epidemic of primary pulmonary hypertension (PPH) occurred in Europe shortly after the introduction of aminorex fumarate, a potent anorexigen." | 7.70 | Aminorex, dexfenfluramine, and primary pulmonary hypertension. ( Kramer, MS; Lane, DA, 1998) |
| "Phentermine and fenfluramine are widely used in the treatment of obesity." | 7.70 | Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss. ( Katz, DA; Maloney, MJ; McConville, BJ; Sutkamp, JC, 1999) |
| "Pulmonary hypertension was diagnosed in a 41-year-old woman after 16 months' use of fenfluramine as a treatment for obesity." | 7.69 | [Pulmonary hypertension following use of fenfluramine for obesity]. ( Maesen, BL; Snijder, RJ; Stricker, BH, 1994) |
| " In order to clarify whether a similar relation exists in obesity and to elucidate the long-term effect of dexfenfluramine (dF) on plasma amino acid profiles and macronutrient selection, we examined 29 obese patients participating in a 12 months double-blind weight loss trial with either dexfenfluramine (dF) (30 mg/day) or placebo (PL) in conjunction with 4." | 7.69 | Long-term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss. ( Andersen, T; Astrup, A; Breum, L; Møller, SE, 1996) |
| "Fenfluramine is a widely prescribed anorectic drug as adjuvant therapy for obesity." | 7.68 | Pulmonary hypertension and fenfluramine. ( Cheriex, EC; Pouwels, HM; Smeets, JL; Wouters, EF, 1990) |
| "In order to study the hypothesized impairment of the serotoninergic system in human obesity, an insulin tolerance test (ITT) was carried out on 12 obese normoprolactinemic women and on 6 normal-weight women before (A) and after (B) the administration of a serotoninergic drug, fenfluramine (60 mg twice a day per os for 7 days)." | 7.67 | Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system. ( Argenio, GF; Bernini, GP; Del Corso, C; Franchi, F; Luisi, M; Sgrò, M; Vivaldi, MS, 1989) |
| "The food hoarding behaviour paradigm (HB) was used to evaluate the modification of the set-point of body weight (BW) regulation induced by dexfenfluramine (D-FF) in rats fed with chow or previously made obese by a cafeteria diet for 51 days." | 7.67 | Effect of dexfenfluramine on body weight set-point: study in the rat with hoarding behaviour. ( Faion, F; Fantino, M; Rolland, Y, 1986) |
| "Pulmonary hypertension developed in two women who had been taking fenfluramine for over eight months for weight reduction." | 7.66 | Pulmonary hypertension and fenfluramine. ( Douglas, JG; Kitchin, AH; Muir, AL; Munro, JF; Proudfoot, AT, 1981) |
| "Fenfluramine is a recently introduced anorexigenic drug for the treatment of obesity." | 7.65 | Fenfluramine-associated hypertension. ( Mabadeje, AF, 1975) |
| "Dexfenfluramine was well tolerated by the majority of patients." | 6.68 | [Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice]. ( Francesconi, M; Geyer, G; Haidinger, G; Kunze, M; Langmayr, N; Prager, R; Schoberberger, R; Toplak, H; von Kalckreuth, G, 1995) |
| "In the previous dF treated patients weight loss after re-introduction of dF was 3." | 6.68 | The effect of withdrawal and re-introduction of dexfenfluramine in the treatment of obesity. ( Adler, G; Ditschuneit, HH; Flechtner-Mors, M, 1996) |
| "Dexfenfluramine treatment was not associated with greater loss of weight." | 6.68 | Evaluation of dexfenfluramine in a weight loss program for obese infertile women. ( Clark, A; Galletly, C; Tomlinson, L, 1996) |
| " Adverse events were usually moderate and transient, occurring at the beginning of treatment." | 6.68 | [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group]. ( Enzi, G, 1997) |
| "Dexfenfluramine (dF) was compared to placebo as adjuvant to a very energy-restricted diet (1." | 6.67 | Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial. ( Andersen, T; Astrup, A; Quaade, F, 1992) |
| "Dexfenfluramine- and placebo-treated patients achieved a similar weight loss (greater than 10% of initial weight, by 39." | 6.67 | Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour. ( Kok, AM; Mathus-Vliegen, EM; Res, AM; van de Voorde, K, 1992) |
| "Rate of weight loss was significantly greater in those taking D-fenfluramine." | 6.66 | A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. ( Brown, D; Goodall, E; Oxtoby, C; Richards, R; Silverstone, T; Watkinson, G, 1988) |
| "Dexfenfluramine has not been directly compared with nonpharmacological measures of weight control such as behaviour modification or exercise programmes." | 6.38 | Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity. ( Heel, RC; McTavish, D, 1992) |
| "Dexfenfluramine is a good candidate for such a use; the demonstration of its long-term efficacy, i." | 6.37 | Place of dexfenfluramine in the management of obesity. ( Guy-Grand, BJ, 1988) |
| "d-Fenfluramine (dF) (15 mg twice daily) has been studied in controlled trials in human obesity and has been shown to increase adherence to diet, to enhance its efficacy, and most importantly, to prevent weight regain when continued over 1 y." | 6.17 | Clinical studies with d-fenfluramine. ( Guy-Grand, B, 1992) |
| "D-fenfluramine treatment markedly improved the maximum relaxant response of aortic rings to acetylcholine, indicating improvement of the defective endothelium-derived relaxation factor system." | 5.30 | Improvement of insulin sensitivity and cardiovascular outcomes in the JCR:LA-cp rat by D-fenfluramine. ( Amy, RM; Brindley, DN; Dolphin, PJ; Graham, SE; Russell, JC, 1998) |
| "d-Fenfluramine is an appetite suppressant drug that acts by releasing serotonin from axon terminals and inhibiting its reuptake." | 5.29 | d-fenfluramine in a rat model of dietary fat-induced obesity. ( Bray, GA; Fisler, JS; Underberger, SJ; York, DA, 1993) |
| "To determine the echocardiographic changes over time of valvular heart lesions in patients who took the weight loss drugs fenfluramine and phentermine." | 5.09 | Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. ( Bailey, KR; Connolly, HM; Grogan, M; Hensrud, DD; Jensen, MD; Miller, FA, 1999) |
| "We tested whether 14 wk of dexfenfluramine (30 mg) or fluoxetine (40 mg) treatment would prevent weight gain after subjects quit smoking." | 5.08 | Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. ( el-Khoury, A; Goldberg, H; McDermott, J; Pingitore, R; Spring, B; Wurtman, J; Wurtman, R, 1995) |
| "To investigate the effect of the serotonin receptor agonist dexfenfluramine on eating habits and weight loss in ambulatory, android type, moderately obese patients with an overconsumption of snacks." | 5.08 | The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks. ( Drent, ML; Koppeschaar, HP; Lutterman, JA; Nieuwenhuyzen Kruseman, AC; van der Veen, EA; Zelissen, PM, 1995) |
| "The results of this study support the longer term use of dexfenfluramine therapy for patients with chronic obesity." | 5.08 | Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. ( Caterson, ID; O'Connor, HT; Richman, RM; Steinbeck, KS, 1995) |
| "To investigate whether a serotoninergic drug such as dexfenfluramine (dF) may have some beneficial effects on energy expenditure (EE) during therapeutic weight reduction, a 3-month study was conducted in a double-blind, placebo-controlled trial." | 5.08 | Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction. ( De Leeuw, IH; Steijaert, MC; Van Gaal, LF; Vansant, GA, 1995) |
| "The effect of the serotonergic agent dexfenfluramine on weight loss, blood pressure, insulin sensitivity and serum lipid levels was determined in a 3-month randomised, double-blind, placebo controlled parallel design study in 50 obese subjects (body mass index 30-44 kg/m2)." | 5.08 | Effect of dexfenfluramine on body weight, blood pressure, insulin resistance and serum cholesterol in obese individuals. ( Gamble, G; Holdaway, IM; Wallace, E; Westbrooke, L, 1995) |
| "To assess the effect of dexfenfluramine on weight loss in obese adolescents, a group of 19 obese girls and boys was treated with a low calorie diet, supplemented with dexfenfluramine." | 5.08 | [Efficacy and safety of dexfenfluramine treatment in obese adolescents]. ( Koehler, B; Małecka-Tendera, E; Muchacka, M; Trzciakowska, A; Wazowski, R, 1996) |
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 5.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| "Dexfenfluramine lowers body weight in obese patients with upper and lower body obesity and reduces the cardiovascular risk factors clustering in upper body obesity." | 5.08 | The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity. ( Adler, G; Ditschuneit, HH; Flechtner-Mors, M, 1996) |
| "To identify parameters predictive of weight loss during treatment with d-fenfluramine." | 5.08 | Predictors of weight loss during treatment with d-fenfluramine. ( Hopman, E; Meinders, AE; Pijl, H; Toornvliet, AC; Westendorp, RG, 1997) |
| "We conclude that women with abdominal obesity have hyperreactivity of the HPA axis to opiod blockage and that dexfenfluramine treatment reduces this hyperactivity." | 5.08 | Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine. ( Boushaki, FZ; Rasio, E; Serri, O, 1997) |
| "The aim of this study was to investigate the potential of dexfenfluramine (dF) for reducing cardiovascular risk factors and improving compliance towards diet in a group of young patients hospitalized for essential obesity of high degree (BMI > or = 35)." | 5.08 | Dexfentluramine in the treatment of juvenile obesity. ( Ardizzi, A; Grugni, G; Guzzaloni, G; Morabito, F; Moro, D, 1997) |
| "Dexfenfluramine aids weight loss and improves glycemic control in obese Chinese NIDDM patients over a 3- to 6-month period." | 5.08 | Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors. ( Chan, JC; Chow, CC; Cockram, CS; Ko, GT; Tsang, LW; Yeung, VT, 1997) |
| "The aim of this work was to investigate the long-term changes of body weight and cardiovascular risk factors after weight reduction with dexfenfluramine (dF) compared to placebo (pI) and additional group therapy." | 5.07 | Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. ( Blomberg, I; Luft, D; Pfohl, M; Schmülling, RM, 1994) |
| "In previous separate studies, dexfenfluramine (DF) and ephedrine/caffeine (EC) have been shown to promote weight loss in obese patients as compared with placebo." | 5.07 | Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. ( Ahlstrøm, F; Breum, L; Frimodt-Møller, J; Pedersen, JK, 1994) |
| "The purpose of this study was to determine the effects of dexfenfluramine on body weight and post-prandial thermogenesis in obese subjects." | 5.07 | Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study. ( Lafreniere, F; Lambert, J; Rasio, E; Serri, O, 1993) |
| "To assess the effect of dexfenfluramine on weight loss, diabetic control and blood lipids in type II diabetics over a three-month period." | 5.07 | Dexfenfluramine in type II diabetes: effect on weight and diabetes control. ( Davis, TM; Findlater, P; Stein, GR; Stewart, GO, 1993) |
| "To evaluate the change in lipids and insulin sensitivity in 10 obese type II diabetic patients after treatment with benfluorex or placebo for 2 wk." | 5.07 | Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| " Pharmacological treatment of obesity has evolved in recent years with the development and licensing of potent serotonin agonists, such as dexfenfluramine (D-F)." | 5.07 | Body weight evolution during dexfenfluramine treatment after initial weight control. ( Finer, N, 1992) |
| "A prospective, randomised case-control trial of an anorectic drug, fenfluramine was conducted on 30 patients of simple obesity." | 5.07 | Effect of fenfluramine on serum T3, T4 and TSH levels in obesity. ( Agrawal, JK; Bajpai, HS; Bhatt, RP; Gupta, SS; Singh, SK, 1992) |
| "Dexfenfluramine has been shown to promote weight loss in overweight people." | 5.07 | The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. ( Molyneaux, LM; Overland, JE; Willey, KA; Yue, DK, 1992) |
| " Pharmacological treatment of obesity has evolved in recent years with the development and licensing of potent serotonin agonists, such as dexfenfluramine (dF), acting as nonstimulant anorectic agents." | 5.07 | Drug therapy after very-low-calorie diets. ( Finer, N; Finer, S; Naoumova, RP, 1992) |
| "The effect of dexfenfluramine (dF) on body weight, blood pressure and noradrenergic activity were studied in 30 obese hypertensive patients randomly divided into two groups and treated for 3 months either with dF (30 mg daily; 16 subjects) or placebo (Pl; 14 subjects)." | 5.07 | Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients. ( Detry, JM; Kolanowski, J; Vanbutsele, R; Younis, LT, 1992) |
| "Directly measured food intake in 31 overweight female smokers to test whether (a) calorie and carbohydrate intakes increase after smoking cessation and (b) double-blind d-fenfluramine (30 mg), a serotonin-releasing drug, suppresses weight gain, overeating, and dysphoric mood associated with stopping smoking." | 5.07 | Weight gain and withdrawal symptoms after smoking cessation: a preventive intervention using d-fenfluramine. ( Gleason, R; Kessler, K; Spring, B; Wurtman, J; Wurtman, R, 1991) |
| "To evaluate whether the inhibitory control of TSH and the stimulatory control of prolactin (PRL) secretion exerted by endogenous serotonin was altered in obesity, 22 obese men and 10 normal controls were tested with TRH (200 micrograms IV bolus) in the presence (experimental test) and absence (control test) of the serotonergic agonist fenfluramine (60 mg PO 90 min before TRH)." | 5.06 | Serotonergic control of TSH and PRL secretion in obese men. ( Camellini, L; Capretti, L; Coiro, V; Davoli, C; Marchesi, C; Passeri, M; Rossi, G; Roti, E; Speroni, G; Volpi, R, 1990) |
| "The efficacy of dexfenfluramine in inducing weight loss and its clinical acceptability were assessed in two studies carried out in a hospital obesity clinic and general practitioner's office." | 5.06 | Effect of 6 months therapy with dexfenfluramine in obese patients: studies in the United Kingdom. ( Craddock, D; Finer, N; Keen, H; Lavielle, R, 1988) |
| "We studied platelet alpha-adrenergic receptor concentration and function in 19 subjects with simple obesity participating in a double-blind, controlled clinical trial of diet and anorexiants (phentermine, fenfluramine, or a combination of the two) or placebo." | 5.05 | Platelet alpha-adrenergic receptors in obesity: alteration with weight loss. ( Banerjee, SP; Hasday, JD; Hershey, LA; Kroening, BH; Sundaresan, PR; Weintraub, M, 1983) |
| "Fifty women with refractory obesity received fenfluramine for 20 weeks." | 5.04 | Plasma fenfluramine levels, weight loss, and side effects. ( Campbell, DB; Ford, MJ; Innes, JA; Munro, JF; Stoddart, ME; Watson, ML, 1977) |
| "Measurements of subjective feeling in 20 patients receiving fenfluramine alternating with placebo and in 19 patients receiving phentermine alternating with placebo indicated that depression of mood occurred four days after fenfluramine withdrawal but no such depression was seen with phentermine." | 5.03 | Withdrawal depression in obese patients after fenfluramine treatment. ( Briggs, M; Steel, JM, 1972) |
| " The use of aminorex, an amphetamine analog that increases norepinephrine levels in the central nervous system, led to an epidemic of primary pulmonary hypertension (PPH) in Europe in the late 1960s and early 1970s." | 4.81 | Anorectic drugs and pulmonary hypertension from the bedside to the bench. ( Michelakis, ED; Weir, EK, 2001) |
| "Sibutramine (BTS 54 524; N-[1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-N,N-dimethylamine hydrochloride monohydrate) is a novel 5-HT (serotonin) and noradrenaline reuptake inhibitor (SNRI) anti-obesity drug." | 4.80 | Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. ( Aspley, S; Cheetham, SC; Heal, DJ; Jackson, HC; Martin, KF; Prow, MR, 1998) |
| " The USA, the European Union and Norway have approved orlistat, a pancreatic lipase inhibitor for weight reduction for up to two years." | 4.80 | [The obesity epidemics--do diet pills have a place in the treatment?]. ( Birkeland, KI; Tonstad, S, 2000) |
| " This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpropanolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets." | 4.80 | Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. ( Ryan, DH, 2000) |
| " Chronic treatment of rats with D-fenfluramine has been shown to decrease the release of cortisol and fatty acids in response to stress, and to improve insulin sensitivity." | 4.79 | Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome. ( Brindley, DN, 1995) |
| "d Fenfluramine (dF) (15 mg twice daily) has been studied in controlled trials in human obesity." | 4.79 | Clinical studies with dexfenfluramine: from past to future. ( Guy-Grand, B, 1995) |
| "Controlled studies have shown that sibutramine produces dose-related weight loss when given in the range 5-30 mg per day, with optimal doses of 10 and 15 mg per day." | 4.79 | Sibutramine--a review of clinical efficacy. ( Lean, ME, 1997) |
| "To assess the validity of the perceptions that appetite-suppressant drugs are ineffective, potentially addictive, and fraught with side effects, we reviewed the effectiveness and safety of two such drugs with purported low abuse potential in the treatment of obesity: mazindol and fenfluramine hydrochloride." | 4.78 | An overview of the efficacy and safety of fenfluramine and mazindol in the treatment of obesity. ( Imperiale, TF; Stahl, KA, 1993) |
| " Benfluorex treatment improves insulin sensitivity and has antihyperglycemic and hypolipidemic effects in human beings and in experimental animals." | 4.78 | [Mode of action of benfluorex. Recent data]. ( Brindley, DN, 1992) |
| "Various animal models of hyperphagia and obesity have made possible the study of the effect on food intake of dexfenfluramine, an agent which both inhibits reuptake and stimulates release of 5 HT." | 4.77 | [Serotonin, food intake and body weight]. ( Rowland, NE; Souquet, AM, 1989) |
| "Fenfluramine has been used for a number of years as a short-term adjunct to diet in the management of obesity." | 4.75 | Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. ( Avery, GS; Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM, 1975) |
| "Dexfenfluramine was better tolerated than ephedrine/caffeine and fluoxetine in short term studies." | 3.78 | Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. ( Davis, R; Faulds, D, 1996) |
| " Body weight, insulin, and leptin were decreased (p < 0." | 3.76 | MR molecular imaging of aortic angiogenesis. ( Cai, K; Caruthers, SD; Huang, W; Lanza, GM; Wickline, SA; Williams, TA; Winter, PM; Zhang, H, 2010) |
| " Her medications included fenfluramine for obesity and hydrochlorothiazide, amlodipine, and atenolol for hypertension." | 3.74 | Spontaneous coronary artery dissection in a woman on fenfluramine. ( Goli, AK; Haddadin, T; Henry, PD; Koduri, M, 2007) |
| "This is a report of health-related quality of life (HRQOL) changes in obese patients completing at least 1 year of outpatient treatment in a weight reduction program combining phentermine-fenfluramine and dietary counseling." | 3.71 | The relationship between health-related quality of life and weight loss. ( Crosby, RD; Hartley, GG; Kolotkin, RL; Nicol, S; Williams, GR, 2001) |
| "Compring with fenfluramine, Guang Dong kudingcha inspissation tea has not effect on configuration of small intestine of adiposity rats (nutrition obesity), but has more strong modulation function on fat tissue lipocyte hypertrophy and quantitative." | 3.70 | [Electron microscope observation on effect of kudingcha inspissation tea on small intestine villus in the adiposity rats]. ( Liu, H; Lu, J, 1999) |
| "In the late 1960s, an epidemic of primary pulmonary hypertension (PPH) occurred in Europe shortly after the introduction of aminorex fumarate, a potent anorexigen." | 3.70 | Aminorex, dexfenfluramine, and primary pulmonary hypertension. ( Kramer, MS; Lane, DA, 1998) |
| "To assess weight loss, as well as the prevalence of valvular heart disease, in 21 obese women who completed 2 years of treatment by fenfluramine and phentermine (fen-phen) in June 1997." | 3.70 | The fen-phen finale: a study of weight loss and valvular heart disease. ( Aber, JL; Berkowitz, RI; Foster, GD; Silvestry, F; St John Sutton, MG; Stunkard, AJ; Vogt, RA; Wadden, TA, 1998) |
| "Phentermine and fenfluramine are widely used in the treatment of obesity." | 3.70 | Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss. ( Katz, DA; Maloney, MJ; McConville, BJ; Sutkamp, JC, 1999) |
| "22 severe binge eaters, 17 moderate binge eaters, and 16 non-binge eaters received phentermine resin 15mg/day and dl-fenfluramine 20mg three times daily over a 6 month period for weight loss." | 3.70 | Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters. ( Alger, SA; Cerulli, J; Fein, S; Howard, L; Malone, M, 1999) |
| "To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk." | 3.70 | Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999) |
| " In the first phase, a non-macronutrient-specific dietary restriction of about 700 kcal/day was prescribed to induce weight loss over 15 weeks, with either fenfluramine or placebo." | 3.70 | Metabolic fitness in active reduced-obese individuals. ( Després, JP; Doucet, E; Imbeault, P; Mauriège, P; Richard, D; Tremblay, A, 1999) |
| "To evaluate cardiovascular status and the prevalence of valvular abnormalities, as assessed by clinical cardiovascular parameters and echocardiography, in patients treated for obesity with dexfenfluramine or phentermine/fenfluramine." | 3.70 | Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. ( Constantine, G; Davis, KD; Gardin, JM; Leung, C; Reid, CL; Schumacher, D, 2000) |
| "Seventeen subjects (10 men and seven women) took part in a 15 week weight loss program which consisted of drug therapy (fenfluramine 60 mg/day) or placebo coupled to an energy restriction (-2930 kJ/day; phase 1) followed by an 18 week low-fat diet-exercise follow-up (phase 2)." | 3.70 | Appetite after weight loss by energy restriction and a low-fat diet-exercise follow-up. ( Alméras, N; Doucet, E; Imbeault, P; Mauriège, P; Richard, D; St-Pierre, S; Tremblay, A, 2000) |
| "Pulmonary hypertension was diagnosed in a 41-year-old woman after 16 months' use of fenfluramine as a treatment for obesity." | 3.69 | [Pulmonary hypertension following use of fenfluramine for obesity]. ( Maesen, BL; Snijder, RJ; Stricker, BH, 1994) |
| " In order to clarify whether a similar relation exists in obesity and to elucidate the long-term effect of dexfenfluramine (dF) on plasma amino acid profiles and macronutrient selection, we examined 29 obese patients participating in a 12 months double-blind weight loss trial with either dexfenfluramine (dF) (30 mg/day) or placebo (PL) in conjunction with 4." | 3.69 | Long-term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss. ( Andersen, T; Astrup, A; Breum, L; Møller, SE, 1996) |
| " Dexfenfluramine (dF), a serotonin releaser and reuptake inhibitor, was used to investigate changes in food intake, body weight development, energy expenditure, respiratory quotient, and substrate oxidation rates for 12 days." | 3.69 | Energy expenditure and substrate oxidation rates of obese rats during a 12-day treatment with dexfenfluramine. ( Aust, L; Boschmann, M; Frenz, U; Noack, R, 1996) |
| "The authors have evaluated the efficacy of d-fenfluramine, a serotoninergic anorectic drug, in 42 obese patients with non-insulin-dependent diabetes mellitus (NIDDM) who not very responded only to the hypocaloric diet or associated therapy with oral hypoglycemic agents." | 3.69 | [The treatment of the obese non-insulin-dependent patient with d-fenfluramine]. ( Coco, MP; Daniele, E, 1996) |
| "The media has been rife with stories about dexfenfluramine, the newest anti-obesity drug." | 3.69 | Iowa patients want new anti-obesity drug. ( Belling, W, 1996) |
| "To validate a variation of a well-established magnetic resonance imaging (MRI) technique to detect liver fat and use it to monitor liver fat changes after treatment with dexfenfluramine in men with non-insulin dependent diabetes mellitus (NIDDM)." | 3.69 | Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM. ( Clark, ML; Hockaday, TD; Marks, SJ; Moore, NR; Pointon, JJ; Ryley, NG; Strauss, BJ, 1997) |
| " Benfluorex has both anorectic and metabolic effects that lower body weight and improve insulin sensitivity in obesity and type 2 diabetes." | 3.69 | Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats. ( Amy, RM; Brindley, DN; Dolphin, PJ; Graham, SE; Russell, JC; Wood, GO, 1997) |
| "Serotonin reuptake inhibitors, such as fluoxetine, fenfluramine, and dexfenfluramine, are frequently used to treat obesity, depression, and bulimia." | 3.69 | Nutritional implications of xerostomia and rampant caries caused by serotonin reuptake inhibitors: a case study. ( Boyd, LD; Dwyer, JT; Papas, A, 1997) |
| "This study evaluated the long-term efficacy and safety of the combination of phentermine and fenfluramine for the treatment of obesity in a private practice setting." | 3.69 | Long-term drug treatment of obesity in a private practice setting. ( Atkinson, RL; Blank, RC; Dhurandhar, NV; Ritch, DL; Schumacher, D, 1997) |
| "To explore the interrelationships between the serotoninergic system and the hypothalamic-pituitary-adrenal (HPA) axis in human obesity, we evaluated cortisol and adrenocorticotropic hormone (ACTH) response to synthetic human corticotropin-releasing hormone (hCRH, 1 microgram/kg intravenously [IV]) before and after stimulation of the serotoninergic system by dextrofenfluramine (d-FF, 30 mg/d for 3 months) in nine obese women." | 3.68 | Serotoninergic receptor activation by dextrofenfluramine enhances the blunted pituitary-adrenal responsiveness to corticotropin-releasing hormone in obese subjects. ( Argenio, GF; Bernini, GP; Birindelli, R; Del Corso, C; Franchi, F; Vivaldi, MS, 1992) |
| "Rats of the JCR:LA-corpulent strain were treated with benfluorex daily at a dose of 25 mg/kg body weight." | 3.68 | Decreased serum lipids, serum insulin and triacylglycerol synthesis in adipose tissue of JCR:LA-corpulent rats treated with benfluorex. ( al-Sieni, AI; Brindley, DN; Hales, P; Russell, JC, 1991) |
| "Fenfluramine is a widely prescribed anorectic drug as adjuvant therapy for obesity." | 3.68 | Pulmonary hypertension and fenfluramine. ( Cheriex, EC; Pouwels, HM; Smeets, JL; Wouters, EF, 1990) |
| "Recent studies suggest that dexfenfluramine (D-fenfluramine), because of its pure serotonergic effect, may be a more potent anti-obesity agent, associated with fewer side-effects than the racemate DL-fenfluramine." | 3.68 | Effect of dexfenfluramine on gastric emptying of a mixed solid-liquid meal in obese subjects. ( Chatterton, B; Horowitz, M; Maddox, A; Shearman, D; Vernon-Roberts, J; Wishart, J, 1990) |
| "In order to study the hypothesized impairment of the serotoninergic system in human obesity, an insulin tolerance test (ITT) was carried out on 12 obese normoprolactinemic women and on 6 normal-weight women before (A) and after (B) the administration of a serotoninergic drug, fenfluramine (60 mg twice a day per os for 7 days)." | 3.67 | Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system. ( Argenio, GF; Bernini, GP; Del Corso, C; Franchi, F; Luisi, M; Sgrò, M; Vivaldi, MS, 1989) |
| " Fenfluramine, an anorexiant drug used in obesity therapy, may have some effects on hypothalamic-pituitary function mediated by serotoninergic stimulation." | 3.67 | Effect of fenfluramine on growth hormone and prolactin secretion in obese subjects. ( Alessi, F; Altomonte, L; Ghirlanda, G; Greco, AV; Manna, R; Zoli, A, 1987) |
| "The food hoarding behaviour paradigm (HB) was used to evaluate the modification of the set-point of body weight (BW) regulation induced by dexfenfluramine (D-FF) in rats fed with chow or previously made obese by a cafeteria diet for 51 days." | 3.67 | Effect of dexfenfluramine on body weight set-point: study in the rat with hoarding behaviour. ( Faion, F; Fantino, M; Rolland, Y, 1986) |
| "5 years old) with a compulsive eating disorder and gross obesity was treated with a combination of behavior therapy and fenfluramine (Ponderax)." | 3.67 | [Treatment of compulsive eating disorders in an autistic girl by combining behavior therapy and pharmacotherapy. Case report]. ( Hackler, J, 1986) |
| "Pulmonary hypertension developed in two women who had been taking fenfluramine for over eight months for weight reduction." | 3.66 | Pulmonary hypertension and fenfluramine. ( Douglas, JG; Kitchin, AH; Muir, AL; Munro, JF; Proudfoot, AT, 1981) |
| "Hydrochlorothiazide, a drug which is often initially prescribed for mild to moderate hypertension, failed to lower blood pressures in 9 of 43 patients but concomitantly elevated plasma norepinephrine (NE) levels in all patients with hypertension." | 3.66 | Fenfluramine potentiation of antihypertensive effects of thiazides. ( Coleman, MD; Kopin, IJ; Lake, CR; Ziegler, MG, 1980) |
| "Fenfluramine is a recently introduced anorexigenic drug for the treatment of obesity." | 3.65 | Fenfluramine-associated hypertension. ( Mabadeje, AF, 1975) |
| "Benfluorex + insulin is a valid alternative for obese patients who remain poorly controlled despite insulin or who require high doses of insulin." | 2.69 | Added benfluorex in obese insulin-requiring type 2 diabetes. ( Bauduceau, B; Brun, JM; Guillon-Metz, F; Leutenegger, M; Martin, C; Nicolino-Peltier, C; Richard, JL; Vannereau, D, 1998) |
| "Dexfenfluramine has been shown to reduce body weight and lower blood pressure in obese individuals." | 2.69 | Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women. ( Adler, G; Ditschuneit, HH; Flechtner-Mors, M; Yip, I, 1998) |
| "These analyses showed that aortic regurgitation of mild or greater severity occurred in 5." | 2.69 | An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. ( Gottdiener, JS; Gwynne, JT; Tighe, JF; Weissman, NJ, 1998) |
| "Most individuals with type 2 diabetes are overweight, and weight loss for them is an important therapeutic objective." | 2.69 | Pharmacologic induction of weight loss to treat type 2 diabetes. ( Bantle, JP; Kwong, CA; Raatz, SK; Redmon, JB; Swanson, JE; Thomas, W, 1999) |
| "Initial weight loss has been used as a predictor of long-term response to obesity drugs." | 2.69 | Initial weight loss as a predictor of response to obesity drugs. ( Atkinson, RL; Blank, RC; Dhurandhar, NV; Schumacher, D, 1999) |
| "Dexfenfluramine was most effective in the short term, behavioural therapy useful long term but only in those who remained within the group; home visits offered no advantage." | 2.68 | The comparison of four weight reduction strategies aimed at overweight diabetic patients. ( Jung, RT; Leese, GP; Manning, RM; Newton, RW, 1995) |
| "6 l h-1) and the terminal half-life tended to be longer (17." | 2.68 | The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ( Cheymol, G; Gellee, C; Poirier, JM; Weissenburger, J, 1995) |
| "Dexfenfluramine was well tolerated by the majority of patients." | 2.68 | [Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice]. ( Francesconi, M; Geyer, G; Haidinger, G; Kunze, M; Langmayr, N; Prager, R; Schoberberger, R; Toplak, H; von Kalckreuth, G, 1995) |
| "In the previous dF treated patients weight loss after re-introduction of dF was 3." | 2.68 | The effect of withdrawal and re-introduction of dexfenfluramine in the treatment of obesity. ( Adler, G; Ditschuneit, HH; Flechtner-Mors, M, 1996) |
| "Dexfenfluramine treatment augments weight and fat loss on a reduced-fat, ad libitum diet, with some evidence for preferential loss of waist fat compared with hip fat." | 2.68 | Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors. ( Carmichael, HE; Swinburn, BA; Wilson, MR, 1996) |
| "Dexfenfluramine treatment was not associated with greater loss of weight." | 2.68 | Evaluation of dexfenfluramine in a weight loss program for obese infertile women. ( Clark, A; Galletly, C; Tomlinson, L, 1996) |
| " Adverse events were usually moderate and transient, occurring at the beginning of treatment." | 2.68 | [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group]. ( Enzi, G, 1997) |
| "Benfluorex hydrochloride has known lipid- and glucose-lowering effects." | 2.67 | Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| "Dexfenfluramine (dF) was compared to placebo as adjuvant to a very energy-restricted diet (1." | 2.67 | Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial. ( Andersen, T; Astrup, A; Quaade, F, 1992) |
| "Dexfenfluramine- and placebo-treated patients achieved a similar weight loss (greater than 10% of initial weight, by 39." | 2.67 | Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour. ( Kok, AM; Mathus-Vliegen, EM; Res, AM; van de Voorde, K, 1992) |
| " Dosing changes were based on an algorithm that aimed to achieve 120% of ideal body weight (IBW) while minimizing adverse effects." | 2.67 | Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine. ( Moscucci, M; Schuster, B; Stein, EC; Sundaresan, PR; Weintraub, M, 1992) |
| "Ritanserin is a new selective 5-HT2 blocker receptor agent." | 2.67 | Impaired growth hormone response to insulin-induced hypoglycaemia in obese patients: restoration blocked by ritanserin after fenfluramine administration. ( Argenio, GF; Bernini, GP; Birindelli, R; Del Corso, C; Franchi, F; Luisi, M; Vivaldi, MS, 1990) |
| " The conclusion is therefore that dF possesses no significant thermogenic effect during long-term administration in human obese subjects." | 2.67 | The effect of long-term dexfenfluramine treatment on 24-hour energy expenditure in man. A double-blind placebo controlled study. ( Andersen, T; Astrup, A; Breum, L; Garby, L; Lammert, O; Nielsen, E; Quaade, F, 1990) |
| "Benfluorex was well tolerated by all patients and no adverse event was reported." | 2.66 | Effects of benfluorex in obese patients with metabolic disorders. ( di Martino, G; Federico, P; Jacono, G; Mattera, E, 1989) |
| "Rate of weight loss was significantly greater in those taking D-fenfluramine." | 2.66 | A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. ( Brown, D; Goodall, E; Oxtoby, C; Richards, R; Silverstone, T; Watkinson, G, 1988) |
| " In conclusion, dextrafenfluramine was proved to be in short term trials an effective and safe tool in overweight control in obese patients." | 2.66 | Efficacy and safety of dexfenfluramine in obese patients: a multicenter study. ( Baggio, B; Bruni, R; Crepaldi, G; Enzi, G; Inelmen, EM, 1988) |
| "Obesity is characterized by increased levels of insulin and by subnormal growth hormone (GH) release." | 2.66 | Effect of fenfluramine on insulin/growth hormone ratio in obese subjects. ( Altomonte, L; Ghirlanda, G; Greco, AV; Manna, R; Zoli, A, 1988) |
| "Fenfluramine-treated participants reported lower hunger ratings and greater fullness in the target supper-to-bedtime period than participants receiving placebo." | 2.65 | Extended-release fenfluramine: patient acceptance and efficacy of evening dosing. ( Dorn, M; Sriwatanakul, K; Sundaresan, PR; Weintraub, M; Weis, OF, 1983) |
| "The dextroamphetamine group was superior in terms of behavioral treatment participation, extent of eating and exercise habit change, and weight loss." | 2.65 | Double-blind evaluation of reinforcing and anorectic actions of weight control medications. Interaction of pharmacological and behavioral treatments. ( Bigelow, GE; Griffiths, RR; Kaliszak, JE; Liebson, I, 1980) |
| "That fenfluramine has dose-related cerebral effects should be remembered in patients with a history of mental illness." | 2.64 | Dreaming, fenfluramine, and vitamin C. ( Mullen, A; Wilson, BP; Wilson, CW, 1977) |
| "Fenfluramine was particularly effective in alleviating anxiety in patients who were initially higher in anxiety." | 2.64 | Emotional symptomatology in obese patients treated with fenfluramine and dextroamphetamine. ( Fisher, E; Hesbacher, P; Perloff, MM; Rickels, K; Rosenfeld, H, 1976) |
| "Drug treatment of obesity offer a possible adjunct, but it may only have modest results, limited by side effects; furthermore, the weight lowering effects last only as long as the drug is being taken and, unfortunately, as soon as the administration is stopped, the weight is regained." | 2.48 | [The pharmacological treatment of obesity: past, present and future]. ( Bedros, JR; Medvegy, M; Pados, G; Simonyi, G, 2012) |
| "Obesity is a chronic disorder that is associated with significant co-morbidity and early mortality." | 2.42 | Anorexigen-induced cardiac valvulopathy and female gender. ( Gross, SB; Naqvi, TZ, 2003) |
| "Obesity is a morbid condition with hemodynamic consequences affecting the systemic and pulmonary circulations leading to a risk of pulmonary hypertension." | 2.41 | [Pulmonary hypertension and obesity]. ( Humbert, M; Ioos, V; Parent, F; Simonneau, G; Sitbon, O; Sztrymf, B, 2002) |
| "Obesity is a major health concern which must be treated." | 2.40 | Pharmacological approaches to intervention. ( Guy-Grand, B, 1997) |
| "Obesity is a major risk factor for morbidity and mortality, and a series of pharmacologic approaches are available for helping to manage the problem." | 2.40 | The pharmacologic approach to the treatment of obesity. ( Abdeen, MA; Frishman, WH; Michaelson, MD; Weiser, M, 1997) |
| "This article focuses on the treatment of obesity and potential results." | 2.40 | Pharmaceutical treatment of obesity. ( Blackburn, GL; Chan, S; Miller, D, 1997) |
| "Obesity is a chronic disease, which similar to diabetes and hypertension, requires long-term treatment." | 2.40 | Obesity. ( Aronne, LJ, 1998) |
| "Obesity is increasing at an alarming rate." | 2.40 | Challenges in obesity management. ( Borrell, L; Foreyt, JP; Haddock, CK; Poston, WS, 1998) |
| "It may be presumed that in the treatment of obesity, in addition to the use of serotoninergic drugs, successes with reducing diets may be enhanced by including periods of high-carbohydrate, low-protein intake." | 2.39 | Appetite regulation by serotoninergic mechanisms and effects of d-fenfluramine. ( Noach, EL, 1994) |
| "Pharmacological treatment of obesity has been neglected as a viable therapeutic option for many years." | 2.39 | Combined drug treatment of obesity. ( Atkinson, RL; Blank, RC; Loper, JF; Lutes, RA; Schumacher, D, 1995) |
| "The syndrome is characterized by insulin insensitivity and an increased control of metabolism by cortisol." | 2.38 | Neuroendocrine regulation and obesity. ( Brindley, DN, 1992) |
| "The resultant weight loss is variable and there appears to be no way of predicting good responders, nor is there evidence that additional weight loss attributable to drug therapy is sustained once treatment is discontinued, although nonpharmacological strategies for preventing weight regain are worthy of exploration." | 2.38 | Appraisal of the clinical value of serotoninergic drugs. ( Hodge, J; Munro, JF; Scott, C, 1992) |
| "Dexfenfluramine also has an original effect on some food intake disorders." | 2.38 | [Dexfenfluramine and feeding behavior. Clinical and pharmacoclinical studies]. ( Fantino, M, 1989) |
| "Increased research focusing on the eating disorders has put the clinician on firmer ground when choosing appropriate psychopharmacologic treatments." | 2.37 | Pharmacologic treatment of eating disorders. ( Gwirtsman, H; Jimerson, DC; Kaye, W; Weintraub, M, 1984) |
| " In some patients, weight regain may be prevented by giving the drug long term but the complications of long-term administration have yet to be evaluated." | 2.37 | The current status of antiobesity drugs. ( Farquhar, DL; Galloway, SM; Munro, JF, 1984) |
| "Fenfluramine (Fintepla) has demonstrated profound reduction in convulsive seizure frequency in DS and was recently approved for use in DS in the US and EU." | 1.62 | Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth. ( Agarwal, A; Ceulemans, B; Cortes, RM; Davis, R; Devinsky, O; Farfel, G; Galer, BS; Gammaiton, AR; Gil-Nagel, A; Knupp, KG; Lock, M; Nabbout, R; Polster, T; Scott Perry, M; Sullivan, J; Wirrell, E, 2021) |
| "Weight gain was prevented with MTEP (3 mg/kg), and weight and adiposity loss was seen with MTEP (10 mg/kg) and dexfenfluramine." | 1.33 | Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice. ( Anderson, J; Bradbury, MJ; Campbell, U; Chapman, D; Cosford, ND; Giracello, D; King, C; Strack, AM; Tehrani, L; Varney, MA, 2005) |
| "D-fenfluramine treatment markedly improved the maximum relaxant response of aortic rings to acetylcholine, indicating improvement of the defective endothelium-derived relaxation factor system." | 1.30 | Improvement of insulin sensitivity and cardiovascular outcomes in the JCR:LA-cp rat by D-fenfluramine. ( Amy, RM; Brindley, DN; Dolphin, PJ; Graham, SE; Russell, JC, 1998) |
| "There were six cases of aortic regurgitation, two cases of mitral regurgitation, and three cases of combined aortic and mitral regurgitation." | 1.30 | A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. ( Derby, LE; Jick, H; Jick, SS; Meier, CR; Vasilakis, C; Weinrauch, LA, 1998) |
| "Marked obesity is an independent risk factor for multi-system morbidity." | 1.30 | [Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants]. ( Goldstein, SE; Levy, Y; Shoenfeld, Y, 1998) |
| " The hypothesis is proposed that this treatment is successful because of the dual and balanced increase in the bioavailability of the neurotransmitters, dopamine and serotonin, in the nucleus accumbens." | 1.29 | Combined dopamine and serotonin agonists: a synergistic approach to alcoholism and other addictive behaviors. ( Hitzig, P, 1993) |
| "After an additional 12 days of treatment, weight gain decreased significantly accompanied by no appetite suppression." | 1.29 | Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants. ( Shaw, WN, 1993) |
| "d-Fenfluramine is an appetite suppressant drug that acts by releasing serotonin from axon terminals and inhibiting its reuptake." | 1.29 | d-fenfluramine in a rat model of dietary fat-induced obesity. ( Bray, GA; Fisler, JS; Underberger, SJ; York, DA, 1993) |
| "Benfluorex treatment and pair feeding decreased serum triacylglycerol concentrations by about 50%; there was a preferential loss of triacylglycerols containing longer chain fatty acids in the males, whereas this selectivity was not seen in the females." | 1.29 | Effects of benfluorex on serum triacylglycerols and insulin sensitivity in the corpulent rat. ( Brindley, DN; Dolphin, PJ; Graham, SE; Russell, JC, 1996) |
| " These studies have demonstrated that chronic administration of fenfluramine (greater than or equal to 10mg/kg body weight) to rats, obese or non-obese, impairs calcium and phosphorus metabolism in the body." | 1.28 | Effects of fenfluramine on the metabolism of calcium and phosphorus in the rat: fenfluramine effects on Ca and P metabolism. ( Ebong, PE; Eka, OU; Ifon, ET; Palaniappan, KG; Umoh, IB, 1992) |
| " Analysis of the dose-response curves indicated an ED50 for the obese rats of 0." | 1.27 | Fenfluramine discrimination in obese and lean Zucker rats: serotonergic mediation of effect. ( Schechter, MD, 1986) |
| " Analysis of the dose-response curves indicated an ED50 for the obese rats of 0." | 1.27 | Effect of dopamine agonists and fenfluramine on discriminative behavior in obese and lean Zucker rats. ( Finkelstein, JA; Schechter, MD, 1985) |
| " There was a strong correlation between drug dosage and plasma levels of fenfluramine." | 1.26 | Plasma fenfluramine levels, weight loss and side effects: a failure to find a relationship. ( Brownell, K; Campbell, DB; Pietrusko, R; Stunkard, A, 1982) |
| "The problem of obesity is not well dealt with in the ordinary diabetes clinic." | 1.25 | A year's experience in a clinic for obese diabetics. ( Goldblatt, R; Jackson, WP; Movsowitz, F, 1975) |
| "Fenfluramine was a valuable adjuvant drug for refractory cases." | 1.25 | A review of obesity and its management in 263 cases. ( Mazansky, H, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 251 (46.40) | 18.7374 |
| 1990's | 238 (43.99) | 18.2507 |
| 2000's | 36 (6.65) | 29.6817 |
| 2010's | 14 (2.59) | 24.3611 |
| 2020's | 2 (0.37) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, M | 1 |
| Daboul, J | 1 |
| Iftikhar, S | 1 |
| Burmeister, C | 1 |
| Ambati, A | 1 |
| Moukarbel, G | 1 |
| Assaly, R | 1 |
| Gil-Nagel, A | 1 |
| Sullivan, J | 1 |
| Ceulemans, B | 2 |
| Wirrell, E | 1 |
| Devinsky, O | 1 |
| Nabbout, R | 1 |
| Knupp, KG | 1 |
| Scott Perry, M | 1 |
| Polster, T | 1 |
| Davis, R | 2 |
| Lock, M | 1 |
| Cortes, RM | 1 |
| Gammaiton, AR | 1 |
| Farfel, G | 1 |
| Galer, BS | 1 |
| Agarwal, A | 1 |
| Schoonjans, AS | 1 |
| Marchau, F | 1 |
| Paelinck, BP | 1 |
| Lagae, L | 1 |
| Gammaitoni, A | 1 |
| Pringsheim, M | 1 |
| Keane, MG | 1 |
| Tribouilloy, C | 3 |
| Maréchaux, S | 2 |
| Jobic, Y | 2 |
| Jeu, A | 1 |
| Ederhy, S | 1 |
| Donal, E | 1 |
| Réant, P | 1 |
| Arnalsteen, E | 1 |
| Boulanger, J | 1 |
| Garban, T | 1 |
| Ennezat, PV | 2 |
| Andréjak, M | 2 |
| Rusinaru, D | 2 |
| Burke, LK | 1 |
| Doslikova, B | 1 |
| D'Agostino, G | 1 |
| Garfield, AS | 2 |
| Farooq, G | 1 |
| Burdakov, D | 1 |
| Low, MJ | 1 |
| Rubinstein, M | 1 |
| Evans, ML | 1 |
| Billups, B | 1 |
| Heisler, LK | 2 |
| Malergue, MC | 1 |
| Bruneval, P | 1 |
| Czitrom, D | 1 |
| Bray, GA | 4 |
| Ayala, ME | 1 |
| Kaplan, LM | 1 |
| Henon, P | 2 |
| Tribouilloy, L | 1 |
| Leleu, F | 1 |
| Sevestre, H | 1 |
| Peltier, M | 1 |
| Caus, T | 1 |
| Astrup, A | 4 |
| Cai, K | 1 |
| Caruthers, SD | 1 |
| Huang, W | 1 |
| Williams, TA | 1 |
| Zhang, H | 1 |
| Wickline, SA | 1 |
| Lanza, GM | 1 |
| Winter, PM | 1 |
| Finger, BC | 1 |
| Dinan, TG | 1 |
| Cryan, JF | 1 |
| Le Ven, F | 1 |
| Habib, G | 1 |
| Gueffet, JP | 1 |
| Eicher, JC | 1 |
| Blanchard-Lemoine, B | 1 |
| Rousseau, J | 1 |
| Etienne, Y | 1 |
| Nau, JY | 2 |
| Surapaneni, P | 1 |
| Vinales, KL | 1 |
| Najib, MQ | 1 |
| Chaliki, HP | 1 |
| Simonyi, G | 1 |
| Pados, G | 1 |
| Medvegy, M | 1 |
| Bedros, JR | 1 |
| Vaughan, SF | 1 |
| Roldan, CA | 1 |
| Gelgand, EA | 1 |
| Decker, P | 1 |
| Prasad, A | 1 |
| Shively, BK | 1 |
| Lu, J | 1 |
| Liu, H | 1 |
| Doucet, E | 6 |
| Imbeault, P | 4 |
| St-Pierre, S | 2 |
| Alméras, N | 5 |
| Mauriège, P | 4 |
| Després, JP | 4 |
| Bouchard, C | 2 |
| Tremblay, A | 7 |
| Naqvi, TZ | 1 |
| Gross, SB | 2 |
| DUNCAN, EH | 1 |
| HYDE, CA | 1 |
| REGAN, NA | 1 |
| SWEETMAN, B | 1 |
| Hess, MA | 1 |
| Blanck, HM | 1 |
| Khan, LK | 1 |
| Serdula, MK | 1 |
| Bradbury, MJ | 1 |
| Campbell, U | 1 |
| Giracello, D | 1 |
| Chapman, D | 1 |
| King, C | 1 |
| Tehrani, L | 1 |
| Cosford, ND | 1 |
| Anderson, J | 1 |
| Varney, MA | 1 |
| Strack, AM | 1 |
| Horton, MR | 1 |
| Tuder, RM | 1 |
| Miller, KJ | 1 |
| Pedrinola, F | 2 |
| Cavaliere, H | 1 |
| Lima, N | 2 |
| Medeiros-Neto, G | 3 |
| Dietz, WH | 1 |
| Whigham, LD | 1 |
| Dhurandhar, NV | 3 |
| Rahko, PS | 1 |
| Atkinson, RL | 5 |
| Goli, AK | 1 |
| Koduri, M | 1 |
| Haddadin, T | 1 |
| Henry, PD | 1 |
| Boulé, NG | 1 |
| Chaput, JP | 1 |
| Richard, D | 4 |
| Fernstrom, JD | 1 |
| Choi, S | 1 |
| Souza, R | 1 |
| Humbert, M | 2 |
| Sztrymf, B | 2 |
| Jaïs, X | 1 |
| Yaïci, A | 1 |
| Le Pavec, J | 1 |
| Parent, F | 2 |
| Hervé, P | 1 |
| Soubrier, F | 1 |
| Sitbon, O | 2 |
| Simonneau, G | 2 |
| Wade, JM | 1 |
| Juneja, P | 1 |
| MacKay, AW | 1 |
| Graham, J | 1 |
| Havel, PJ | 1 |
| Tecott, LH | 1 |
| Goulding, EH | 1 |
| Metz, L | 1 |
| Mercier, J | 1 |
| Joanisse, DR | 1 |
| Stunkard, AJ | 9 |
| Craighead, LW | 3 |
| O'Brien, R | 1 |
| Douglas, JG | 3 |
| Gough, J | 1 |
| Preston, PG | 2 |
| Frazer, I | 1 |
| Haslett, C | 1 |
| Chalmers, SR | 1 |
| Munro, JF | 16 |
| Gwirtsman, H | 1 |
| Kaye, W | 1 |
| Weintraub, M | 13 |
| Jimerson, DC | 1 |
| Orosco, M | 1 |
| Bremond, J | 1 |
| Jacquot, C | 1 |
| Cohen, Y | 1 |
| Sundaresan, PR | 9 |
| Hershey, LA | 1 |
| Kroening, BH | 1 |
| Hasday, JD | 2 |
| Banerjee, SP | 1 |
| Sriwatanakul, K | 1 |
| Weis, OF | 1 |
| Dorn, M | 1 |
| Stunkard, A | 3 |
| Barbieri, C | 1 |
| Magnoni, V | 2 |
| Rauhe, WG | 1 |
| Zanasi, S | 1 |
| Caldara, R | 1 |
| Ferrari, C | 1 |
| Mushlin, AI | 1 |
| Lockwood, DH | 1 |
| Wurtman, JJ | 3 |
| Galloway, SM | 1 |
| Farquhar, DL | 1 |
| Wurtman, RJ | 1 |
| Chernow, B | 1 |
| Lake, CR | 2 |
| Cook, D | 1 |
| Coyle, J | 1 |
| Hughes, P | 1 |
| Coleman, MD | 2 |
| Ziegler, MG | 2 |
| Villanueva, L | 2 |
| Casanueva, F | 2 |
| Peñalva, A | 1 |
| Cuesta, M | 1 |
| Tomé, S | 1 |
| Gómez-Recio, M | 1 |
| Cabezas-Cerrato, J | 2 |
| Kitchin, AH | 1 |
| Muir, AL | 1 |
| Proudfoot, AT | 1 |
| Hager, T | 1 |
| Hopkins, SJ | 1 |
| Bigelow, GE | 2 |
| Griffiths, RR | 2 |
| Liebson, I | 2 |
| Kaliszak, JE | 1 |
| Israsena, T | 2 |
| Israngkura, M | 1 |
| Srivuthana, S | 1 |
| Wechsler, JG | 2 |
| Ditschuneit, H | 2 |
| Misra, NP | 1 |
| Bhambal, SA | 1 |
| Yesikar, SS | 1 |
| Bellani, RK | 1 |
| Boni, S | 1 |
| Bonini, LM | 1 |
| Zecca, L | 1 |
| Bareggi, SR | 1 |
| Iselin, HU | 1 |
| Burckhardt, P | 1 |
| Guagnano, MT | 3 |
| Di Vincenzo, M | 2 |
| Sensi, S | 3 |
| Della Loggia, F | 2 |
| Friedman, RB | 1 |
| Kindy, P | 1 |
| Reinke, JA | 1 |
| Pietrusko, R | 1 |
| Brownell, K | 1 |
| Campbell, DB | 4 |
| Gaul, G | 1 |
| Blazek, G | 1 |
| Deutsch, E | 1 |
| Heeger, H | 1 |
| Rath, R | 1 |
| Grafnetter, D | 1 |
| O'Brien, RM | 1 |
| Brownell, KD | 2 |
| Grinker, JA | 1 |
| Drewnowski, A | 1 |
| Enns, M | 1 |
| Kissileff, H | 1 |
| Kopin, IJ | 1 |
| Wales, JK | 3 |
| Mendoza Espejo, R | 1 |
| Díaz Pérez de Madrid, J | 1 |
| Buitrago, F | 1 |
| Spring, B | 2 |
| Wurtman, J | 4 |
| Wurtman, R | 3 |
| el-Khoury, A | 1 |
| Goldberg, H | 1 |
| McDermott, J | 1 |
| Pingitore, R | 1 |
| Björntorp, P | 2 |
| Lemieux, S | 1 |
| Lamarche, B | 1 |
| Prud'homme, D | 1 |
| Moorjani, S | 2 |
| Brun, LD | 2 |
| Gagné, C | 2 |
| Lupien, PJ | 2 |
| Brindley, DN | 11 |
| Blundell, JE | 3 |
| Hill, AJ | 2 |
| Drent, ML | 2 |
| Zelissen, PM | 2 |
| Koppeschaar, HP | 2 |
| Nieuwenhuyzen Kruseman, AC | 1 |
| Lutterman, JA | 1 |
| van der Veen, EA | 2 |
| Manning, RM | 2 |
| Jung, RT | 2 |
| Leese, GP | 2 |
| Newton, RW | 2 |
| Cheymol, G | 1 |
| Weissenburger, J | 1 |
| Poirier, JM | 1 |
| Gellee, C | 1 |
| O'Connor, HT | 1 |
| Richman, RM | 1 |
| Steinbeck, KS | 1 |
| Caterson, ID | 1 |
| Maesen, BL | 1 |
| Snijder, RJ | 1 |
| Stricker, BH | 2 |
| Toornvliet, AC | 4 |
| Pijl, H | 6 |
| Meinders, AE | 7 |
| Rowland, NE | 5 |
| VanItallie, TB | 1 |
| Russell, JC | 6 |
| Van Gaal, LF | 1 |
| Vansant, GA | 1 |
| Steijaert, MC | 1 |
| De Leeuw, IH | 1 |
| Cugini, P | 1 |
| Battisti, P | 1 |
| Paggi, A | 1 |
| Di Stasio, ME | 1 |
| Di Palma, L | 1 |
| Morelli, F | 1 |
| Pisculli, M | 2 |
| Lavielle, R | 4 |
| Greco, AV | 4 |
| Mingrone, G | 2 |
| Capristo, E | 1 |
| De Gaetano, A | 2 |
| Ghirlanda, G | 4 |
| Castagneto, M | 1 |
| Khan, M | 1 |
| Lum, CT | 1 |
| Rao, V | 1 |
| Hubbard, VS | 1 |
| Voelker, R | 1 |
| Noach, EL | 1 |
| Bremer, JM | 1 |
| Scott, RS | 1 |
| Lintott, CJ | 1 |
| Perozim, L | 1 |
| Wajchenberg, BL | 1 |
| Pfohl, M | 1 |
| Luft, D | 1 |
| Blomberg, I | 1 |
| Schmülling, RM | 1 |
| Kogon, MM | 1 |
| Kräuchi, K | 1 |
| Van der Velde, P | 1 |
| Van der Werf, H | 1 |
| Keller, U | 1 |
| Hitzig, P | 1 |
| Stahl, KA | 1 |
| Imperiale, TF | 1 |
| Breum, L | 3 |
| Pedersen, JK | 1 |
| Ahlstrøm, F | 1 |
| Frimodt-Møller, J | 1 |
| Lee, S | 1 |
| Chan, K | 1 |
| Shaw, WN | 1 |
| Ditschuneit, HH | 4 |
| Flechtner-Mors, M | 4 |
| Dolderer, M | 1 |
| Fulda, U | 1 |
| Bianchi, R | 2 |
| Bongers, V | 2 |
| Bravenboer, B | 2 |
| Erkelens, DW | 2 |
| Tataranni, PA | 1 |
| Raguso, C | 1 |
| Tacchino, RM | 1 |
| Fisler, JS | 1 |
| Underberger, SJ | 1 |
| York, DA | 1 |
| Lafreniere, F | 1 |
| Lambert, J | 1 |
| Rasio, E | 2 |
| Serri, O | 2 |
| Scalfi, L | 1 |
| D'Arrigo, E | 1 |
| Carandente, V | 1 |
| Coltorti, A | 1 |
| Contaldo, F | 1 |
| Medeiros-Neto, GA | 1 |
| Berlin, I | 1 |
| Puech, AJ | 1 |
| Mathus-Vliegen, LM | 1 |
| Res, AM | 2 |
| Stewart, GO | 1 |
| Stein, GR | 1 |
| Davis, TM | 1 |
| Findlater, P | 1 |
| Del Ponte, A | 2 |
| D'Orazio, N | 1 |
| Di Giacomo, G | 1 |
| Tritella, T | 1 |
| Bitti, G | 1 |
| Martines, G | 1 |
| Andersen, PH | 1 |
| Richelsen, B | 1 |
| Bak, J | 1 |
| Schmitz, O | 1 |
| Sørensen, NS | 1 |
| Pedersen, O | 1 |
| Holdaway, IM | 1 |
| Wallace, E | 1 |
| Westbrooke, L | 1 |
| Gamble, G | 1 |
| Rothman, RB | 1 |
| Møller, SE | 1 |
| Andersen, T | 3 |
| Prager, R | 2 |
| Geyer, G | 1 |
| Haidinger, G | 1 |
| Francesconi, M | 1 |
| Langmayr, N | 1 |
| Schoberberger, R | 1 |
| Toplak, H | 1 |
| von Kalckreuth, G | 1 |
| Kunze, M | 1 |
| Adler, G | 3 |
| Nightingale, SL | 1 |
| Manson, JE | 2 |
| Faich, GA | 3 |
| Boisaubin, EV | 1 |
| Dourish, CT | 2 |
| Guy-Grand, B | 5 |
| Blank, RC | 3 |
| Loper, JF | 1 |
| Schumacher, D | 4 |
| Lutes, RA | 1 |
| Małecka-Tendera, E | 1 |
| Koehler, B | 1 |
| Muchacka, M | 1 |
| Wazowski, R | 1 |
| Trzciakowska, A | 1 |
| Sonka, J | 1 |
| Marek, J | 1 |
| Svacina, S | 1 |
| Sucharda, P | 1 |
| Stĕpán, J | 1 |
| Boschmann, M | 2 |
| Aust, L | 1 |
| Frenz, U | 2 |
| Noack, R | 2 |
| Kars, ME | 1 |
| Cohen, AF | 1 |
| Frölich, M | 1 |
| Schoemaker, HC | 1 |
| Brandenburg, HC | 1 |
| Daniele, E | 1 |
| Coco, MP | 1 |
| Marks, SJ | 2 |
| Moore, NR | 2 |
| Clark, ML | 2 |
| Strauss, BJ | 2 |
| Hockaday, TD | 2 |
| Adèr, HJ | 1 |
| Angell, M | 1 |
| Kassirer, JP | 1 |
| Barkin, RL | 1 |
| Clemenson, ND | 1 |
| Jordaan, GP | 1 |
| Roberts, MC | 1 |
| Emsley, RA | 1 |
| Schenck, CH | 1 |
| Mahowald, MW | 1 |
| Belling, W | 1 |
| Pontiroli, AE | 1 |
| Pacchioni, M | 1 |
| Piatti, PM | 1 |
| Cassisa, C | 1 |
| Camisasca, R | 1 |
| Pozza, G | 1 |
| van der Merwe, MT | 1 |
| Wing, JR | 1 |
| Celgow, LH | 1 |
| Gray, IP | 1 |
| Lönn, L | 1 |
| Joffe, BI | 1 |
| Lönnroth, PN | 1 |
| Murphy, CM | 1 |
| Hopman, E | 2 |
| Elte-de Wever, BM | 1 |
| Swinburn, BA | 2 |
| Carmichael, HE | 2 |
| Wilson, MR | 2 |
| Galletly, C | 1 |
| Clark, A | 1 |
| Tomlinson, L | 1 |
| Graham, SE | 3 |
| Dolphin, PJ | 3 |
| Bihm, B | 1 |
| Sztuke-Fournier, A | 1 |
| Budenholzer, B | 1 |
| Fishman, AP | 1 |
| Monego, ET | 1 |
| Peixoto, Mdo R | 1 |
| Jardim, PC | 1 |
| Sousa, AL | 1 |
| Braga, VL | 1 |
| Moura, MF | 1 |
| Fogelson, DL | 1 |
| Goldstein, DJ | 1 |
| Cerda, JJ | 1 |
| Kushner, R | 1 |
| Héraïef, E | 2 |
| Sukkari, SR | 1 |
| Voelkel, NF | 1 |
| Clarke, WR | 1 |
| Higenbottam, T | 1 |
| Faulds, D | 1 |
| Ryley, NG | 1 |
| Pointon, JJ | 1 |
| Lean, ME | 1 |
| Shuster, J | 1 |
| Anchors, M | 1 |
| Westendorp, RG | 1 |
| Wadden, TA | 3 |
| Berkowitz, RI | 3 |
| Vogt, RA | 2 |
| Steen, SN | 1 |
| Foster, GD | 3 |
| Boushaki, FZ | 1 |
| Grugni, G | 1 |
| Guzzaloni, G | 1 |
| Ardizzi, A | 1 |
| Moro, D | 1 |
| Morabito, F | 1 |
| Chow, CC | 1 |
| Ko, GT | 1 |
| Tsang, LW | 1 |
| Yeung, VT | 1 |
| Chan, JC | 1 |
| Cockram, CS | 1 |
| Weiser, M | 1 |
| Frishman, WH | 1 |
| Michaelson, MD | 1 |
| Abdeen, MA | 1 |
| Enzi, G | 3 |
| Amy, RM | 2 |
| Wood, GO | 1 |
| Wen, PY | 1 |
| Feske, SK | 1 |
| Teoh, SK | 1 |
| Stieg, PE | 1 |
| Curfman, GD | 1 |
| Healy, BP | 1 |
| Jackson, HC | 2 |
| Needham, AM | 1 |
| Hutchins, LJ | 1 |
| Mazurkiewicz, SE | 1 |
| Heal, DJ | 2 |
| DeMeo, MT | 1 |
| Mobarhan, S | 1 |
| Mikolaitis, S | 1 |
| Kazi, N | 1 |
| Hancock, EW | 1 |
| Boyd, LD | 1 |
| Dwyer, JT | 1 |
| Papas, A | 1 |
| Preval, H | 1 |
| Pakyurek, AM | 1 |
| Blackburn, GL | 1 |
| Miller, D | 1 |
| Chan, S | 1 |
| Marinella, MA | 1 |
| Berrettoni, BA | 1 |
| Carruba, MO | 1 |
| Nisoli, E | 1 |
| Hirsch, J | 1 |
| Scheen, AJ | 2 |
| Ritch, DL | 1 |
| Aronne, LJ | 1 |
| Aurigemma, GP | 1 |
| Gaasch, WH | 1 |
| Pocock, SJ | 1 |
| Abdalla, M | 1 |
| Bagri, S | 1 |
| Reddy, G | 1 |
| Connolly, J | 1 |
| Verni, C | 1 |
| Trilling, J | 1 |
| Kelso, E | 1 |
| Shiesha, S | 1 |
| Leutenegger, M | 1 |
| Bauduceau, B | 1 |
| Brun, JM | 2 |
| Guillon-Metz, F | 1 |
| Martin, C | 1 |
| Nicolino-Peltier, C | 1 |
| Richard, JL | 1 |
| Vannereau, D | 1 |
| Yip, I | 1 |
| Kramer, MS | 1 |
| Lane, DA | 1 |
| Capriotti, T | 1 |
| Silvestry, F | 1 |
| St John Sutton, MG | 1 |
| Aber, JL | 2 |
| Zimmer, JE | 1 |
| Gregory, RJ | 1 |
| Poston, WS | 2 |
| Foreyt, JP | 2 |
| Borrell, L | 1 |
| Haddock, CK | 2 |
| Deitel, M | 1 |
| Khan, MA | 1 |
| Herzog, CA | 1 |
| St Peter, JV | 1 |
| Hartley, GG | 2 |
| Madlon-Kay, R | 1 |
| Dick, CD | 1 |
| Asinger, RW | 2 |
| Vessey, JT | 1 |
| Jick, H | 2 |
| Vasilakis, C | 1 |
| Weinrauch, LA | 1 |
| Meier, CR | 1 |
| Jick, SS | 1 |
| Derby, LE | 2 |
| Weissman, NJ | 2 |
| Tighe, JF | 1 |
| Gottdiener, JS | 1 |
| Gwynne, JT | 1 |
| Devereux, RB | 1 |
| Cannistra, LB | 1 |
| Cannistra, AJ | 1 |
| Chaine, B | 1 |
| Morand, JJ | 1 |
| Folchetti, G | 1 |
| Hesse, S | 1 |
| Jean-Pastor, MJ | 1 |
| Bonerandi, JJ | 1 |
| Aspley, S | 1 |
| Prow, MR | 1 |
| Martin, KF | 1 |
| Cheetham, SC | 1 |
| Parisi, AF | 1 |
| Shapiro, S | 1 |
| Cowley, G | 1 |
| Springen, K | 1 |
| Katz, DA | 1 |
| Maloney, MJ | 1 |
| Sutkamp, JC | 1 |
| McConville, BJ | 1 |
| Wang, W | 1 |
| Zhao, DZ | 1 |
| Sun, BH | 1 |
| Myers, MW | 1 |
| Silvestry, FE | 2 |
| Sutton, MG | 1 |
| St John Sutton, M | 1 |
| Redmon, JB | 1 |
| Raatz, SK | 1 |
| Kwong, CA | 1 |
| Swanson, JE | 1 |
| Thomas, W | 1 |
| Bantle, JP | 1 |
| Ryan, DH | 3 |
| Helmcke, F | 1 |
| Sander, G | 1 |
| Volaufova, J | 1 |
| Greenway, F | 1 |
| Subramaniam, P | 1 |
| Glancy, DL | 1 |
| Pi-Sunyer, FX | 1 |
| Gillen, G | 1 |
| Porter, JR | 1 |
| Svec, F | 2 |
| Alger, SA | 1 |
| Malone, M | 1 |
| Cerulli, J | 1 |
| Fein, S | 1 |
| Howard, L | 1 |
| Greenway, FL | 1 |
| Rood, JC | 1 |
| Tucker, EW | 1 |
| Smith, SR | 1 |
| Hensrud, DD | 1 |
| Connolly, HM | 1 |
| Grogan, M | 1 |
| Miller, FA | 1 |
| Bailey, KR | 1 |
| Jensen, MD | 1 |
| Nguyen, T | 1 |
| Porter, J | 1 |
| Kancherla, MK | 1 |
| Salti, HI | 1 |
| Mulderink, TA | 1 |
| Parker, M | 1 |
| Bonow, RO | 1 |
| Mehlman, DJ | 1 |
| Gardin, JM | 1 |
| Constantine, G | 1 |
| Davis, KD | 1 |
| Leung, C | 1 |
| Reid, CL | 1 |
| St Pierre, S | 1 |
| Cheng, TO | 1 |
| Allen, S | 1 |
| Henderson, J | 1 |
| Goldstein, SE | 1 |
| Levy, Y | 1 |
| Shoenfeld, Y | 1 |
| Tonstad, S | 1 |
| Birkeland, KI | 1 |
| Carvajal, A | 1 |
| García del Pozo, J | 1 |
| Martín de Diego, I | 1 |
| Rueda de Castro, AM | 1 |
| Velasco, A | 1 |
| Bickerdike, MJ | 1 |
| Vickers, SP | 1 |
| Michelakis, ED | 1 |
| Weir, EK | 1 |
| Golden, F | 1 |
| Mark, S | 1 |
| Tsay, R | 1 |
| Gilbert, W | 1 |
| Growdon, J | 1 |
| Kolotkin, RL | 1 |
| Crosby, RD | 1 |
| Williams, GR | 1 |
| Nicol, S | 1 |
| Howlin, D | 1 |
| Dill, PL | 1 |
| Ericsson, M | 1 |
| Tellier, P | 1 |
| Ioos, V | 1 |
| Kasowski, MA | 1 |
| Hipkin, LJ | 1 |
| Davis, JC | 1 |
| Hoebel, BG | 1 |
| Kaliszak, J | 1 |
| Antelman, SM | 1 |
| Caggiula, AR | 1 |
| Black, CA | 1 |
| Edwards, DJ | 1 |
| Mullen, A | 2 |
| Wilson, CW | 5 |
| Wilson, BP | 1 |
| Carr, RH | 1 |
| Ipaktchi, M | 1 |
| Thenen, SW | 1 |
| Stern, JS | 1 |
| Larsen, S | 1 |
| Vejtorp, L | 1 |
| Hornnes, P | 1 |
| Bechgaard, H | 1 |
| Sestoft, L | 1 |
| Lyngsoe, J | 1 |
| Bizzi, A | 2 |
| Tacconi, MT | 1 |
| Tognoni, G | 1 |
| Morselli, PL | 1 |
| Garattini, S | 3 |
| Pugnoli, C | 1 |
| Bandini, L | 1 |
| Caronna, S | 1 |
| Ciarlini, E | 1 |
| Magnati, G | 1 |
| Strata, A | 1 |
| Tirelli, F | 1 |
| Foran, K | 1 |
| Innes, JA | 3 |
| Watson, ML | 2 |
| Ford, MJ | 4 |
| Stoddart, ME | 2 |
| Schiøttz-Christensen, E | 1 |
| Förster, H | 2 |
| Huth, K | 2 |
| Koch, E | 2 |
| Tunali, G | 2 |
| Tatti, P | 1 |
| Vasta, M | 1 |
| Belbusti, F | 1 |
| Calò, C | 1 |
| Donati, L | 1 |
| Brumby, KH | 1 |
| Götestam, KG | 2 |
| Odumosu, A | 2 |
| Chandraprasert, S | 1 |
| Marugo, M | 1 |
| Giusti, M | 1 |
| Cocco, R | 1 |
| Bolognesi, F | 1 |
| Reitano, A | 1 |
| Hudson, KD | 1 |
| Pudel, VE | 1 |
| Oetting, M | 1 |
| Cairella, M | 3 |
| Baritussio, A | 1 |
| Rigon, G | 1 |
| Molinari, M | 1 |
| Inelmen, EM | 2 |
| Crepaldi, G | 3 |
| Kirby, MJ | 1 |
| Pleece, SA | 1 |
| Redfern, PH | 1 |
| Gómez, M | 1 |
| Camarero, E | 2 |
| Pinder, RM | 1 |
| Brogden, RN | 1 |
| Sawyer, PR | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Macrae, SM | 1 |
| Petrie, JC | 2 |
| Mowat, JA | 1 |
| Bewsher, PD | 1 |
| Stowers, JM | 1 |
| Galloway, DB | 1 |
| Logie, AW | 1 |
| Balasse, EO | 2 |
| Couturier, E | 1 |
| Kornitzer, M | 1 |
| Degre, S | 1 |
| Adadevoh, BK | 1 |
| Hooper, AC | 3 |
| Campbell, IW | 1 |
| Millar, J | 1 |
| Tomlinson, SA | 1 |
| Lines, JG | 1 |
| Greenfield, MA | 1 |
| Owen, JH | 2 |
| Hossain, M | 1 |
| Kesson, CM | 1 |
| Ireland, JT | 1 |
| Bleehen, SS | 1 |
| Edwards, IR | 1 |
| Clark, RG | 1 |
| Rickels, K | 2 |
| Hesbacher, P | 2 |
| Fisher, E | 1 |
| Perloff, MM | 1 |
| Rosenfeld, H | 1 |
| Weisweiler, P | 3 |
| Schwandt, P | 3 |
| Tisdale, SA | 1 |
| Ervin, DK | 1 |
| Otim, MA | 1 |
| Asmal, AC | 1 |
| Leary, WP | 1 |
| Deppe, W | 1 |
| Lockett, CJ | 1 |
| Hofmann, GG | 1 |
| Kalachi, Y | 1 |
| Rosenfeld, JB | 1 |
| Ost, LG | 1 |
| Maneksha, S | 1 |
| Bomson, L | 1 |
| Parker, CH | 2 |
| Scott, ME | 1 |
| Nelson, PG | 1 |
| Schindler, H | 1 |
| Bielesz, G | 1 |
| O'Malley, K | 1 |
| Stevenson, IH | 1 |
| West, M | 1 |
| Jackson, WP | 2 |
| Movsowitz, F | 1 |
| Goldblatt, R | 1 |
| Opitz, K | 1 |
| Miller, DS | 1 |
| Evans, E | 1 |
| Samuel, P | 1 |
| Burland, WL | 1 |
| Sulaiman, WR | 1 |
| Johnson, RH | 1 |
| Rennie, MJ | 1 |
| Wells, HM | 1 |
| Wilton, D | 1 |
| Riveline, B | 1 |
| Davidson, DL | 1 |
| Mawdsley, C | 1 |
| Campbell, C | 1 |
| Duhault, J | 2 |
| Boulander, M | 1 |
| Beregi, L | 1 |
| Mabadeje, AF | 2 |
| Chlouverakis, C | 1 |
| Mazansky, H | 1 |
| Widhalm, K | 1 |
| Deutsch, J | 1 |
| Steuber, U | 1 |
| Bengen, F | 1 |
| Dekant, A | 2 |
| Kutschera, D | 1 |
| Weiland, D | 1 |
| Bernini, GP | 5 |
| Argenio, GF | 5 |
| Del Corso, C | 6 |
| Vivaldi, MS | 6 |
| Birindelli, R | 2 |
| Franchi, F | 6 |
| Quaade, F | 2 |
| Silverstone, T | 4 |
| Cantley, P | 1 |
| Turner, P | 4 |
| Finer, N | 4 |
| Schutz, Y | 1 |
| Munger, R | 1 |
| Dériaz, O | 1 |
| Jéquier, E | 1 |
| McTavish, D | 1 |
| Heel, RC | 1 |
| Leigh, FS | 1 |
| Kaufman, LN | 1 |
| Young, JB | 1 |
| Lledo Carreres, M | 1 |
| Lajo Garrido, JL | 1 |
| Gonzalez Rico, M | 1 |
| Navarro Polo, JN | 1 |
| Escobar Cava, P | 1 |
| Aznar Saliente, T | 1 |
| Bories, JM | 1 |
| Bauret, P | 1 |
| Larrey, D | 1 |
| Michel, H | 1 |
| Mathus-Vliegen, EM | 1 |
| van de Voorde, K | 1 |
| Kok, AM | 1 |
| Ifon, ET | 1 |
| Ebong, PE | 1 |
| Palaniappan, KG | 1 |
| Umoh, IB | 1 |
| Eka, OU | 1 |
| Gupta, SS | 1 |
| Agrawal, JK | 1 |
| Bajpai, HS | 1 |
| Bhatt, RP | 1 |
| Singh, SK | 1 |
| Cairella, G | 1 |
| Graziani, P | 1 |
| Mirante, MG | 1 |
| Taghva, AR | 1 |
| Madan, M | 2 |
| Schuster, B | 6 |
| Balder, A | 2 |
| Lasagna, L | 1 |
| Cox, C | 3 |
| Ginsberg, G | 1 |
| Stein, EC | 4 |
| Byrne, L | 3 |
| Moscucci, M | 1 |
| Averbuch, M | 2 |
| Willey, KA | 1 |
| Molyneaux, LM | 1 |
| Overland, JE | 1 |
| Yue, DK | 1 |
| Finer, S | 1 |
| Naoumova, RP | 1 |
| Kolanowski, J | 1 |
| Younis, LT | 1 |
| Vanbutsele, R | 1 |
| Detry, JM | 1 |
| Hales, P | 2 |
| al-Sieni, AI | 2 |
| Elia, D | 1 |
| Auclair, J | 1 |
| Rey, C | 1 |
| Scott, C | 1 |
| Hodge, J | 1 |
| Balabolkin, MI | 1 |
| Novikova, OM | 1 |
| Levitskaia, ZI | 1 |
| Santoni, R | 3 |
| Sgró, M | 2 |
| Gleason, R | 1 |
| Kessler, K | 1 |
| Laurent-Jaccard, A | 1 |
| Paolisso, G | 1 |
| Salvatore, T | 1 |
| Lefèbvre, PJ | 1 |
| Andersson, B | 1 |
| Zimmermann, ME | 1 |
| Hedner, T | 1 |
| Luisi, M | 3 |
| Argenio, G | 1 |
| Bernini, G | 1 |
| Monzani, F | 1 |
| Baschieri, L | 1 |
| Bertolozzi, G | 1 |
| Coiro, V | 1 |
| Passeri, M | 1 |
| Capretti, L | 1 |
| Speroni, G | 1 |
| Davoli, C | 1 |
| Marchesi, C | 1 |
| Rossi, G | 1 |
| Camellini, L | 1 |
| Volpi, R | 1 |
| Roti, E | 1 |
| Petraroli, AR | 1 |
| Riganelli, S | 1 |
| Saracino, A | 1 |
| Siani, V | 1 |
| Lammert, O | 1 |
| Nielsen, E | 1 |
| Garby, L | 1 |
| Ivković-Lazar, T | 1 |
| Stokić, E | 1 |
| Lepsanović, L | 1 |
| Carlton, J | 3 |
| Pouwels, HM | 1 |
| Smeets, JL | 1 |
| Cheriex, EC | 1 |
| Wouters, EF | 1 |
| Horowitz, M | 2 |
| Maddox, A | 1 |
| Wishart, J | 1 |
| Vernon-Roberts, J | 2 |
| Chatterton, B | 1 |
| Shearman, D | 1 |
| Apfelbaum, M | 1 |
| Gries, A | 1 |
| Lefebvre, P | 1 |
| di Martino, G | 1 |
| Federico, P | 1 |
| Mattera, E | 1 |
| Jacono, G | 1 |
| Fantino, M | 2 |
| Louvet, JP | 1 |
| Souquet, AM | 1 |
| Goodall, E | 2 |
| Oxtoby, C | 1 |
| Richards, R | 1 |
| Watkinson, G | 1 |
| Brown, D | 1 |
| Derôme-Tremblay, M | 1 |
| Nathan, C | 2 |
| Van Itallie, TB | 1 |
| Bruni, R | 1 |
| Baggio, B | 1 |
| Craddock, D | 1 |
| Keen, H | 1 |
| Guy-Grand, BJ | 1 |
| Caccia, S | 2 |
| Mennini, T | 1 |
| Samanin, R | 1 |
| Bielmann, P | 1 |
| Nadeau, A | 1 |
| el-Refai, MF | 1 |
| Chan, TM | 1 |
| Klompenhouwer, JL | 1 |
| van Tilburg, AJ | 1 |
| Moleman, P | 1 |
| Pepplinkhuizen, L | 1 |
| Altomonte, L | 2 |
| Zoli, A | 2 |
| Manna, R | 2 |
| Rolland, Y | 2 |
| Fracasso, C | 1 |
| Guiso, G | 1 |
| Alessi, F | 1 |
| Cluysenaer, OJ | 1 |
| Tjoeng, MM | 1 |
| Schechter, MD | 2 |
| Faion, F | 1 |
| Hackler, J | 1 |
| Kemnitz, JW | 1 |
| Collins, PJ | 1 |
| Tuckwell, V | 1 |
| Shearman, DJ | 1 |
| Finkelstein, JA | 1 |
| Garrow, JS | 1 |
| Belton, EA | 1 |
| Daniels, A | 1 |
| Kaufmann, NA | 2 |
| Blondheim, SH | 2 |
| Morris, DF | 1 |
| Goldrick, RB | 2 |
| Havenstein, N | 2 |
| Whyte, HM | 1 |
| Waal-Manning, HJ | 1 |
| Simpson, FO | 1 |
| Lawson, AA | 2 |
| Strong, JA | 2 |
| Peattie, P | 2 |
| Roscoe, P | 1 |
| Gibson, A | 1 |
| Mroczek, WJ | 1 |
| Lee, WR | 1 |
| Finnerty, FA | 1 |
| Shannon, PJ | 1 |
| Leonard, D | 1 |
| Kidson, MA | 1 |
| Rathgeber, R | 1 |
| Sapeika, N | 4 |
| Abdel-Kader, MM | 1 |
| Mashaly, M | 1 |
| Abdel-Aziz, MT | 1 |
| Court, JM | 2 |
| Lele, RD | 1 |
| Joshi, VR | 1 |
| Nathwani, AN | 1 |
| Bentwich, T | 1 |
| Bentwich, Z | 1 |
| Jensen, PS | 1 |
| Kirk, L | 1 |
| Rastogi, GK | 1 |
| Sharma, PL | 1 |
| Saini, GS | 1 |
| Kanen, VL | 1 |
| Jorgensen, F | 1 |
| Steel, JM | 2 |
| Duncan, LJ | 2 |
| Sainani, GS | 1 |
| Fulambarkar, AM | 1 |
| Khurana, BK | 1 |
| Persson, I | 2 |
| Andersen, U | 1 |
| Deckert, T | 2 |
| Myking, O | 1 |
| Bassoe, HH | 1 |
| Closs, K | 1 |
| Haug, E | 1 |
| Myklebust, R | 1 |
| Cameron, DC | 1 |
| Kennedy, WP | 1 |
| Samuel, PD | 1 |
| Crompton, GK | 1 |
| Andersen, UD | 1 |
| Rozen, P | 1 |
| Superstine, E | 1 |
| Durnin, JV | 1 |
| Womersley, J | 1 |
| Datey, KK | 1 |
| Kelkar, PN | 1 |
| Pandya, RS | 1 |
| Nestel, PJ | 1 |
| Dykes, MH | 1 |
| Laurent, LP | 1 |
| Sproule, BC | 1 |
| Vignati, E | 1 |
| Gaind, R | 2 |
| Nussey, AM | 1 |
| Sedgwick, JP | 4 |
| Guemes Diaz, JF | 1 |
| Messerich, J | 1 |
| Dunleavy, DL | 1 |
| Oswald, I | 1 |
| Cabezas Cerrato, J | 2 |
| Catalán, E | 1 |
| Vila, T | 1 |
| Fernández-Cruz, A | 2 |
| Pawan, GS | 1 |
| Jespersen, S | 1 |
| Dekant, H | 1 |
| Krause, W | 1 |
| Jervell, J | 1 |
| Schjott, F | 1 |
| Stewart, E | 1 |
| Dykes, JR | 2 |
| Gómez Pérez, M | 1 |
| Marco-Mur, AL | 1 |
| Wilton, TD | 1 |
| Bernier, A | 1 |
| Sicot, N | 1 |
| Le Douarec, JC | 1 |
| Silverstone, JT | 1 |
| Cooper, RM | 1 |
| Begg, RR | 1 |
| Follows, OJ | 1 |
| De Sereday, MS | 1 |
| Efron, HR | 1 |
| De Compte, DV | 1 |
| Raffo del Campo, MA | 1 |
| Bacon, GE | 1 |
| Lowrey, GH | 1 |
| Elliott, BW | 1 |
| Briggs, M | 1 |
| Bartlett, DW | 1 |
| Harding, T | 2 |
| Zwarenstein, H | 1 |
| Kaplan, ER | 1 |
| Traherne, JB | 1 |
| Seaton, DA | 1 |
| O'Connor, CA | 1 |
| Brodbin, P | 1 |
| Abdallah, AH | 1 |
| Kneebone, GM | 1 |
| Gibson, AM | 1 |
| Liebermeister, H | 1 |
| Probst, G | 1 |
| Jahnke, K | 1 |
| Ramírez Soto, E | 1 |
| Delgado Urdapilleta, J | 1 |
| Spence, AW | 1 |
| Medvei, VC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)[NCT01725256] | Phase 2 | 29 participants (Actual) | Interventional | 2012-11-30 | Terminated (stopped due to Terminated early dt to acquisition of Sponsor and change in corporate priorities) | ||
| A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension[NCT01725269] | Phase 2 | 17 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to Terminated early dt acquisition of Sponsor and change in corporate priorities) | ||
| Abdominal Obesity as a Therapeutic Target: Long-term Benefits of Abdominal Fat Loss and Weight Stabilization in High-risk Abdominally Obese Dyslipidemic Patients With the Features of the Metabolic Syndrome (SYNERGIE Study)[NCT06158191] | 186 participants (Actual) | Interventional | 2004-03-26 | Completed | |||
| Effect of Sulphate-bicarbonate-calcium Water Consumption on the Body Weight and Gut Microbiota Composition in Overweight and Obese Patients Under Low-calorie Diet[NCT02154230] | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to failure to enroll) | |||
| Hunger and Satiety Perception in Patients With Anorexia Nervosa[NCT02932046] | 47 participants (Actual) | Observational | 2014-02-28 | Completed | |||
| [NCT00000506] | Phase 2 | 0 participants | Interventional | 1983-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
83 reviews available for fenfluramine and Obesity
| Article | Year |
|---|---|
Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population.
Topics: Adult; Appetite Depressants; Dexfenfluramine; Epilepsies, Myoclonic; Fenfluramine; Heart Valve Disea | 2017 |
Pharmacological targeting of the serotonergic system for the treatment of obesity.
Topics: Animals; Appetite Regulation; Eating; Fenfluramine; Humans; Hypothalamus; Mice; Mice, Knockout; Mode | 2009 |
Pharmacologic therapies for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; | 2010 |
[The pharmacological treatment of obesity: past, present and future].
Topics: Amides; Anti-Obesity Agents; Anticonvulsants; Antidepressive Agents; Basal Metabolism; Benzazepines; | 2012 |
Anorexigen-induced cardiac valvulopathy and female gender.
Topics: Adult; Appetite Depressants; Dexfenfluramine; Echocardiography; Female; Fenfluramine; Heart Valve Di | 2003 |
Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity.
Topics: Animals; Fenfluramine; Humans; Norfenfluramine; Obesity; Receptor, Serotonin, 5-HT2C; Serotonin Rece | 2005 |
The development of tolerance to drugs that suppress food intake.
Topics: Animals; Appetite Depressants; Body Weight; Cyclobutanes; Drug Tolerance; Eating; Fenfluramine; Huma | 2008 |
Pharmacologic treatment of eating disorders.
Topics: Anorexia Nervosa; Anticonvulsants; Antidepressive Agents; Antidepressive Agents, Tricyclic; Central | 1984 |
The involvement of brain serotonin in excessive carbohydrate snacking by obese carbohydrate cravers.
Topics: Adult; Animals; Brain; Dietary Carbohydrates; Dietary Proteins; Fenfluramine; Food Preferences; Huma | 1984 |
The current status of antiobesity drugs.
Topics: Adult; Amphetamine; Appetite Depressants; Body Weight; Child; Diethylpropion; Dose-Response Relation | 1984 |
[Long-term results of treatment of obesity].
Topics: Appetite Depressants; Behavior Therapy; Diet, Reducing; Fasting; Fenfluramine; Follow-Up Studies; Hu | 1980 |
Anorectic agents lower a body weight set point.
Topics: Animals; Appetite Depressants; Appetite Regulation; Behavior Therapy; Body Weight; Dextroamphetamine | 1982 |
Neuroendocrine abnormalities in human obesity.
Topics: Animals; Corticotropin-Releasing Hormone; Female; Fenfluramine; Humans; Hydroxyindoleacetic Acid; Ma | 1995 |
The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications.
Topics: Adipose Tissue; Cardiovascular Diseases; Fenfluramine; Humans; Hyperlipidemias; Insulin Resistance; | 1995 |
Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome.
Topics: Animals; Fatty Acids; Fatty Acids, Nonesterified; Fenfluramine; Glucocorticoids; Humans; Hydrocortis | 1995 |
[Control of appetite with dexfenfluramine in treatment of obesity].
Topics: Appetite; Feeding Behavior; Fenfluramine; Humans; Obesity | 1995 |
Metabolic abnormalities linked to obesity: effects of dexfenfluramine in the corpulent rat.
Topics: Animals; Disease Models, Animal; Fenfluramine; Male; Obesity; Rats; Rats, Mutant Strains | 1995 |
Appetite regulation by serotoninergic mechanisms and effects of d-fenfluramine.
Topics: Animals; Appetite; Fenfluramine; Humans; Models, Biological; Obesity; Rats; Receptors, Serotonin; Se | 1994 |
An overview of the efficacy and safety of fenfluramine and mazindol in the treatment of obesity.
Topics: Adult; Body Weight; Clinical Trials as Topic; Double-Blind Method; Female; Fenfluramine; Humans; Mal | 1993 |
Dexfenfluramine influences dietary compliance and eating behaviors of obese subjects.
Topics: Feeding Behavior; Fenfluramine; Humans; Obesity; Patient Compliance | 1994 |
Mechanisms for the effects of benfluorex on the obese-diabetic-dyslipidemic syndrome.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hyperlipidemias; Hypogl | 1993 |
[Therapy of obesity].
Topics: Animals; Appetite Depressants; Body Mass Index; Diet, Reducing; Fenfluramine; Gastric Balloon; Gastr | 1995 |
Multiple serotonin receptors: opportunities for new treatments for obesity?
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Appetite Depressants; Fenfluramine; Humans; Hyperph | 1995 |
Clinical studies with dexfenfluramine: from past to future.
Topics: Appetite Depressants; Fenfluramine; Humans; Obesity; Weight Loss | 1995 |
Combined drug treatment of obesity.
Topics: Adrenergic Agents; Appetite Depressants; Benzocaine; Drug Therapy, Combination; Ephedrine; Fenfluram | 1995 |
[Drug treatment of obesity].
Topics: Adult; Appetite Depressants; Female; Fenfluramine; Humans; Leptin; Male; Mazindol; Obesity; Proteins | 1996 |
The treatment of obesity. A call for prudence and professionalism.
Topics: Advertising; Appetite Depressants; Drug Prescriptions; Fenfluramine; Humans; Obesity; Phentermine; U | 1997 |
Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
Topics: Animals; Appetite Depressants; Drug Tolerance; Feeding Behavior; Fenfluramine; Humans; Hypertension, | 1996 |
Pharmacological approaches to intervention.
Topics: Anti-Obesity Agents; Appetite Depressants; Fenfluramine; Humans; Obesity; Phentermine; Time Factors; | 1997 |
Sibutramine--a review of clinical efficacy.
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Body Weight; Cardiovascular Physio | 1997 |
The pharmacologic approach to the treatment of obesity.
Topics: Adrenergic beta-Agonists; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Energy Metabo | 1997 |
Pharmaceutical treatment of obesity.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Drug Combinations; Fenfluramine; Humans; Obesity; Phe | 1997 |
Obesity.
Topics: Appetite Depressants; Behavior; Body Mass Index; Diet, Reducing; Exercise; Female; Fenfluramine; Hum | 1998 |
Selections from current literature: pharmacological treatment of obesity.
Topics: Appetite Depressants; Drug Therapy, Combination; Fenfluramine; Humans; Hypertension, Pulmonary; Obes | 1998 |
In search of a 'magic' pill to treat obesity: the rise and fall of 'Fen-Phen'.
Topics: Appetite Depressants; Fenfluramine; Humans; Obesity; Phentermine | 1998 |
Challenges in obesity management.
Topics: 1-Naphthylamine; Adrenergic beta-Agonists; Appetite Depressants; Behavior Therapy; Caffeine; Cyclobu | 1998 |
Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.
Topics: Animals; Biogenic Monoamines; Cyclobutanes; Dextroamphetamine; Energy Metabolism; Fenfluramine; Huma | 1998 |
Appetite suppressants and cardiac valvulopathy. Current clinical perspectives.
Topics: Appetite Depressants; Dexfenfluramine; Fenfluramine; Heart Valve Diseases; Humans; Hypertension, Pul | 1999 |
[The obesity epidemics--do diet pills have a place in the treatment?].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Fenfluramine; Humans; Lactones; Leptin; Obe | 2000 |
Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: a meta-analysis.
Topics: Appetite Depressants; Dexfenfluramine; Double-Blind Method; Fenfluramine; Humans; MEDLINE; Obesity; | 2000 |
Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity.
Topics: Adrenergic Agents; Appetite Depressants; Cyclobutanes; Dexfenfluramine; Dextroamphetamine; Fenfluram | 2000 |
5-HT2C receptor modulation and the treatment of obesity.
Topics: Animals; Appetite Depressants; Cyclobutanes; Disease Models, Animal; Fenfluramine; Humans; Obesity; | 1999 |
Appetite suppressants and valvular heart disease.
Topics: Age Factors; Appetite Depressants; Dexfenfluramine; Drug Therapy, Combination; Fenfluramine; Heart V | 2001 |
Anorectic drugs and pulmonary hypertension from the bedside to the bench.
Topics: Aminorex; Appetite Depressants; Dexfenfluramine; Fenfluramine; Humans; Hypertension, Pulmonary; Obes | 2001 |
Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials.
Topics: Amphetamines; Anti-Obesity Agents; Benzphetamine; Cyclobutanes; Fenfluramine; Humans; Obesity; Rando | 2002 |
Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifacts.
Topics: Appetite Depressants; Fenfluramine; Heart Valve Diseases; Humans; Hypertension, Pulmonary; Obesity; | 2001 |
[Pulmonary hypertension and obesity].
Topics: Aminorex; Fenfluramine; Hemodynamics; Humans; Hypertension, Pulmonary; Hypothyroidism; Hypoxia; Obes | 2002 |
Weight control programs.
Topics: Amphetamines; Animals; Appetite; Behavior Therapy; Chorionic Gonadotropin; Diet, Reducing; Energy In | 1977 |
Clinical aspects of the treatment of obesity by drugs: a review.
Topics: Amphetamines; Appetite Depressants; Clinical Trials as Topic; Diethylpropion; Drug Tolerance; Female | 1979 |
Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity.
Topics: Adult; Age Factors; Analgesics; Anticonvulsants; Appetite Depressants; Body Temperature; Central Ner | 1975 |
Peripheral and metabolic effects of fenfluramine, 780SE, norfenfluramine and hydroxyethylnorfenfluramine--a review.
Topics: Adipose Tissue; Amphetamines; Animals; Autonomic Nervous System; Blood Pressure; Cats; Dogs; Fenflur | 1975 |
Treatment of obesity. Appetite suppressant drugs and intestinal by-pass surgery.
Topics: Amphetamines; Appetite Depressants; Diethylpropion; Fenfluramine; Humans; Intestine, Small; Mazindol | 1976 |
Drugs, appetite and obesity: a personal odyssey.
Topics: Amphetamine; Animals; Eating; Fenfluramine; Humans; Hunger; Obesity | 1992 |
The management of obesity. One view.
Topics: Diet, Reducing; Fenfluramine; Food Deprivation; Humans; Jejunoileal Bypass; Obesity; Obesity, Morbid | 1992 |
Benefit:risk consideration in long-term therapy with dexfenfluramine.
Topics: Fenfluramine; Humans; Obesity; Placebos; Risk Factors | 1992 |
INDEX (international dexfenfluramine study) as a model for long-term pharmacotherapy of obesity in the 1990s.
Topics: Fenfluramine; Humans; Obesity; Recurrence; Time Factors; Weight Loss | 1992 |
Effect of dexfenfluramine on energy expenditure in man.
Topics: Adult; Basal Metabolism; Body Temperature Regulation; Energy Metabolism; Female; Fenfluramine; Human | 1992 |
Neuroendocrine regulation and obesity.
Topics: Animals; Diabetes Complications; Endocrine Glands; Fenfluramine; Humans; Hydrocortisone; Hyperlipide | 1992 |
Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity.
Topics: Animals; Fenfluramine; Humans; Obesity | 1992 |
[Mode of action of benfluorex. Recent data].
Topics: Animals; Arteriosclerosis; Diabetes Mellitus, Type 2; Drug Interactions; Fatty Acids; Female; Fenflu | 1992 |
Serotoninergic system: therapeutic implications in obesity.
Topics: Appetite Depressants; Feeding and Eating Disorders; Female; Fenfluramine; Humans; Male; Obesity; Ser | 1992 |
Clinical studies with d-fenfluramine.
Topics: Body Weight; Female; Fenfluramine; Humans; Obesity | 1992 |
Appraisal of the clinical value of serotoninergic drugs.
Topics: Appetite Depressants; Fenfluramine; Fluoxetine; Humans; Obesity; Serotonin; Weight Loss | 1992 |
Very low calorie diets and recently developed anti-obesity drugs for treating overweight in non-insulin-dependent diabetics.
Topics: Adrenergic beta-Agonists; Diabetes Mellitus, Type 2; Diet, Reducing; Fenfluramine; Fluoxetine; Human | 1990 |
[Regulation of food intake and the treatment of obesity using centrally-active serotonergic drugs].
Topics: Adult; Energy Intake; Energy Metabolism; Female; Fenfluramine; Fluoxetine; Humans; Male; Middle Aged | 1991 |
Dexfenfluramine. Its place in weight control.
Topics: Animals; Feeding Behavior; Fenfluramine; Humans; Obesity | 1990 |
Tolerance to fenfluramine anorexia: fact or fiction?
Topics: Animals; Behavior Therapy; Body Weight; Brain; Brain Chemistry; Drug Tolerance; Feeding Behavior; Fe | 1986 |
[Dexfenfluramine and feeding behavior. Clinical and pharmacoclinical studies].
Topics: Animals; Depression; Feeding Behavior; Fenfluramine; Humans; Hyperphagia; Models, Biological; Obesit | 1989 |
[Serotonin, food intake and body weight].
Topics: Animals; Body Weight; Disease Models, Animal; Eating; Feeding Behavior; Fenfluramine; Humans; Hyperp | 1989 |
Serotoninergic mechanisms in human feeding: the pharmacological evidence.
Topics: Amitriptyline; Antipsychotic Agents; Cyproheptadine; Diet; Feeding Behavior; Fenfluramine; Food Pref | 1986 |
Obesity, genetics, and ponderal set point.
Topics: Energy Metabolism; Environment; Fenfluramine; Humans; Obesity | 1988 |
Place of dexfenfluramine in the management of obesity.
Topics: Fenfluramine; Humans; Obesity | 1988 |
Progress in assessing the role of serotonin in the control of food intake.
Topics: Eating; Fenfluramine; Humans; Obesity; Serotonin | 1988 |
Disorders of food intake. Excessive carbohydrate snack intake among a class of obese people.
Topics: Dietary Carbohydrates; Emotions; Feeding and Eating Disorders; Feeding Behavior; Fenfluramine; Human | 1987 |
Pharmacological treatments that affect CNS activity: serotonin.
Topics: Animals; Antidepressive Agents; Body Weight; Compulsive Behavior; Eating; Energy Intake; Feeding and | 1987 |
Serotonin manipulations and the structure of feeding behaviour.
Topics: Amphetamine; Animals; Appetite; Brain; Conditioning, Operant; Feeding Behavior; Fenfluramine; Food P | 1986 |
Clinical use of appetite suppressants.
Topics: Amphetamines; Appetite Depressants; Body Weight; Diethylpropion; Double-Blind Method; Drug Tolerance | 1986 |
[Obesity-background and treatment].
Topics: Age Factors; Amphetamine; Appetite Regulation; Body Weight; Diet, Reducing; Fatty Acids; Female; Fen | 1972 |
The management of obesity.
Topics: Adolescent; Adult; Amphetamine; Body Weight; Child; Chlorphentermine; Diet, Reducing; Diethylpropion | 1972 |
[Fenfluramine and drug dependence].
Topics: Appetite Depressants; Fenfluramine; Humans; Obesity; Psychoses, Substance-Induced; Substance-Related | 1973 |
[Pharmacology and biochemistry of fenfluramine].
Topics: Amphetamine; Animals; Appetite; Body Temperature Regulation; Cats; Central Nervous System; Depressio | 1973 |
New thoughts on obesity and its treatment.
Topics: Amphetamine; Diet, Reducing; Dietary Carbohydrates; Dietary Fats; Fenfluramine; Humans; Lipid Metabo | 1968 |
Obesity--the health hazard of our time.
Topics: Amphetamine; Appetite Depressants; Chorionic Gonadotropin; Diet, Reducing; Fasting; Fenfluramine; Fl | 1971 |
172 trials available for fenfluramine and Obesity
| Article | Year |
|---|---|
Is DL-fenfluramine a potentially helpful drug therapy in overweight adolescent subjects?
Topics: Adolescent; Body Mass Index; Child; Dose-Response Relationship, Drug; Exercise; Female; Fenfluramine | 1994 |
Glucose homeostasis predicts weight gain: prospective and clinical evidence.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Fenfluramine; Glucose Tolerance Test; | 2008 |
Effect of weight loss on lactate transporter expression in skeletal muscle of obese subjects.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Caloric Restriction; Citrate (si)-Synthase; Female; Fenfl | 2008 |
Controlled trial of behaviour therapy, pharmacotherapy, and their combination in the treatment of obesity.
Topics: Behavior Therapy; Blood Pressure; Body Weight; Clinical Trials as Topic; Female; Fenfluramine; Human | 1980 |
Long-term efficacy of fenfluramine in treatment of obesity.
Topics: Body Weight; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Female; Fen | 1983 |
Platelet alpha-adrenergic receptors in obesity: alteration with weight loss.
Topics: Adult; Body Weight; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female | 1983 |
Extended-release fenfluramine: patient acceptance and efficacy of evening dosing.
Topics: Adolescent; Adult; Behavior Therapy; Body Weight; Clinical Trials as Topic; Delayed-Action Preparati | 1983 |
Drugs and diet therapy.
Topics: Animals; Appetite Depressants; Behavior Therapy; Body Weight; Clinical Trials as Topic; Female; Fenf | 1983 |
Effect of fenfluramine on prolactin secretion in obese patients: evidence for serotoninergic regulation of prolactin in man.
Topics: Adult; Aldosterone; Blood Pressure; Female; Fenfluramine; Growth Hormone; Humans; Hydrocortisone; Ma | 1983 |
A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
Topics: Adolescent; Adult; Body Weight; Clinical Trials as Topic; Diet; Double-Blind Method; Drug Therapy, C | 1984 |
Sequencing of behavior therapy and pharmacotherapy for obesity.
Topics: Adolescent; Adult; Appetite; Behavior Therapy; Combined Modality Therapy; Female; Fenfluramine; Huma | 1984 |
[Insulin secretion induced by glucose or arginine in non-obese volunteers. Action of fenfluramine].
Topics: Adult; Arginine; Blood Glucose; Female; Fenfluramine; Glucose; Humans; Insulin; Insulin Secretion; I | 1982 |
Double-blind evaluation of reinforcing and anorectic actions of weight control medications. Interaction of pharmacological and behavioral treatments.
Topics: Adult; Behavior Therapy; Body Weight; Clinical Trials as Topic; Dextroamphetamine; Double-Blind Meth | 1980 |
Treatment of childhood obesity.
Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Female; Fenflura | 1980 |
Balanced hypocaloric diet versus protein-sparing modified fast in the treatment of obesity: a comparative study.
Topics: Adolescent; Adult; Amphetamines; Appetite Depressants; Diet, Reducing; Dietary Proteins; Energy Inta | 1982 |
Behavior therapy and pharmacotherapy for obesity.
Topics: Adult; Aged; Behavior Therapy; Body Weight; Female; Fenfluramine; Humans; Male; Middle Aged; Obesity | 1981 |
[Effectiveness of serotonergic agonists in the treatment of obese patients].
Topics: Adult; Appetite Depressants; Body Mass Index; Diet, Reducing; Female; Fenfluramine; Fluoxetine; Foll | 1995 |
Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation.
Topics: Adult; Analysis of Variance; Appetite Depressants; Body Mass Index; Dietary Carbohydrates; Dietary P | 1995 |
The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks.
Topics: Adult; Alcohol Drinking; Ambulatory Care; Dietary Carbohydrates; Double-Blind Method; Eating; Feedin | 1995 |
The comparison of four weight reduction strategies aimed at overweight diabetic patients.
Topics: Adolescent; Adult; Aged; Behavior Therapy; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Me | 1995 |
The pharmacokinetics of dexfenfluramine in obese and non-obese subjects.
Topics: Administration, Oral; Adult; Cross-Over Studies; Female; Fenfluramine; Humans; Injections, Intraveno | 1995 |
Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
Topics: Adolescent; Adult; Anthropometry; Body Composition; Body Constitution; Cardiovascular Diseases; Chol | 1995 |
Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction.
Topics: Adolescent; Adult; Anthropometry; Body Temperature Regulation; Diet, Reducing; Double-Blind Method; | 1995 |
Effects of dexfenfluramine on free fatty acid turnover and oxidation in obese patients with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acids, Nonesterified; Female; Fenfluramine; Huma | 1995 |
Dexfenfluramine reduces cardiovascular risk factors.
Topics: Apolipoproteins B; Body Mass Index; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Choleste | 1994 |
The effect of hypocaloric diet with and without D-fenfluramine treatment on growth hormone release after growth hormone-releasing factor stimulation in patients with android obesity.
Topics: Adult; Analysis of Variance; Anthropometry; Combined Modality Therapy; Diet, Reducing; Female; Fenfl | 1994 |
Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Cardiovascular Diseases; Cholesterol; Female; Fe | 1994 |
Psychological and metabolic effects of dietary carbohydrates and dexfenfluramine during a low-energy diet in obese women.
Topics: Adult; Affect; Blood Pressure; Body Weight; Diet, Reducing; Dietary Carbohydrates; Energy Intake; En | 1994 |
Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice.
Topics: Adolescent; Adult; Aged; Blood Pressure; Body Mass Index; Caffeine; Double-Blind Method; Ephedrine; | 1994 |
Dexfenfluramine influences dietary compliance and eating behaviors of obese subjects.
Topics: Feeding Behavior; Fenfluramine; Humans; Obesity; Patient Compliance | 1994 |
Endocrine and metabolic effects of dexfenfluramine in patients with android obesity.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Anthropometry; Body Mass Index; Circadian Rhyt | 1993 |
Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; | 1993 |
Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study.
Topics: Adult; Blood Chemical Analysis; Body Temperature; Body Weight; Calorimetry, Indirect; Double-Blind M | 1993 |
The acute effect of dexfenfluramine on resting metabolic rate and postprandial thermogenesis in obese subjects: a double-blind placebo-controlled study.
Topics: Adult; Basal Metabolism; Body Temperature Regulation; Calorimetry, Indirect; Double-Blind Method; En | 1993 |
Dexfenfluramine in type II diabetes: effect on weight and diabetes control.
Topics: Adult; Aged; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; | 1993 |
Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients.
Topics: Apolipoprotein A-I; Apolipoproteins B; Appetite Depressants; Blood Glucose; C-Peptide; Cholesterol; | 1993 |
Influence of short-term dexfenfluramine therapy on glucose and lipid metabolism in obese non-diabetic patients.
Topics: Adipose Tissue; Adult; Biological Transport; Blood Glucose; C-Peptide; Double-Blind Method; Female; | 1993 |
Effect of dexfenfluramine on body weight, blood pressure, insulin resistance and serum cholesterol in obese individuals.
Topics: Adult; Blood Pressure; Body Mass Index; Body Weight; Cholesterol; Dose-Response Relationship, Drug; | 1995 |
[Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice].
Topics: Adult; Aged; Appetite Depressants; Austria; Body Weight; Combined Modality Therapy; Diet, Reducing; | 1995 |
The effect of withdrawal and re-introduction of dexfenfluramine in the treatment of obesity.
Topics: Adult; Female; Fenfluramine; Humans; Obesity; Weight Loss | 1996 |
[Efficacy and safety of dexfenfluramine treatment in obese adolescents].
Topics: Adolescent; Chromaffin Granules; Energy Intake; Female; Fenfluramine; Humans; Male; Obesity; Triglyc | 1996 |
Specific stimulation of brain serotonin mediated neurotransmission by dexfenfluramine does not restore growth hormone responsiveness in obese women.
Topics: Adult; Brain; Cross-Over Studies; Drug Therapy, Combination; Female; Fenfluramine; Follicular Phase; | 1996 |
The influence of chronic administration of the serotonin agonist dexfenfluramine on responsiveness to corticotropin releasing hormone and growth hormone-releasing hormone in moderately obese people.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Corticotropin-Releasing Hormone; Female; Fenfl | 1995 |
Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
Topics: 3-Hydroxybutyric Acid; Appetite Depressants; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mel | 1996 |
Serotoninergic drug-induced weight loss in carbohydrate craving obese patients.
Topics: Appetite Depressants; Body Mass Index; Dietary Carbohydrates; Energy Intake; Female; Fenfluramine; F | 1996 |
Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors.
Topics: Adipose Tissue; Adult; Aged; Appetite Depressants; Body Composition; Cardiovascular Diseases; Dietar | 1996 |
Evaluation of dexfenfluramine in a weight loss program for obese infertile women.
Topics: Adult; Appetite Depressants; Combined Modality Therapy; Double-Blind Method; Exercise; Female; Fenfl | 1996 |
The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity.
Topics: Adult; Analysis of Variance; Appetite Depressants; Body Mass Index; Body Weight; Cardiovascular Dise | 1996 |
[Different therapies in the treatment of obesity in hypertensive patients].
Topics: Adult; Aged; Blood Pressure; Body Mass Index; Body Weight; Diet, Fat-Restricted; Double-Blind Method | 1996 |
[Tolerance and acceptability of dexfenfluramine in the long-term treatment of obesity in private practice. ESIM Group].
Topics: Adult; Appetite Depressants; Diet, Reducing; Female; Fenfluramine; Humans; Male; Middle Aged; Obesit | 1997 |
Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
Topics: Animals; Appetite Depressants; Drug Tolerance; Feeding Behavior; Fenfluramine; Humans; Hypertension, | 1996 |
Predictors of weight loss during treatment with d-fenfluramine.
Topics: Adult; Analysis of Variance; Appetite Depressants; Body Weight; Energy Intake; Female; Fenfluramine; | 1997 |
Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach.
Topics: Adult; Affect; Appetite Depressants; Behavior Therapy; Feeding Behavior; Female; Fenfluramine; Human | 1997 |
Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine.
Topics: Adrenocorticotropic Hormone; Adult; Body Constitution; Body Mass Index; Corticotropin-Releasing Horm | 1997 |
Dexfentluramine in the treatment of juvenile obesity.
Topics: Blood Pressure; Female; Fenfluramine; Humans; Male; Obesity; Placebos; Selective Serotonin Reuptake | 1997 |
Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
Topics: Adult; Appetite Depressants; Blood Glucose; Blood Pressure; Body Mass Index; China; Diabetes Mellitu | 1997 |
[A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Appetite Depressants; Diabetes Mellitus; Diabetes Mel | 1997 |
Lower fat intake as a predictor of initial and sustained weight loss in obese subjects consuming an otherwise ad libitum diet.
Topics: Adult; Aged; Appetite Depressants; Body Mass Index; Dietary Fats; Exercise; Female; Fenfluramine; Hu | 1998 |
Added benfluorex in obese insulin-requiring type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus | 1998 |
Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women.
Topics: Adult; Appetite Depressants; Blood Glucose; Blood Pressure; Body Composition; Body Constitution; Bod | 1998 |
The comparison of four weight reduction strategies aimed at overweight patients with diabetes mellitus: four-year follow-up.
Topics: Ambulatory Care; Appetite Depressants; Diabetes Mellitus; Dietetics; Female; Fenfluramine; Follow-Up | 1998 |
An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
Topics: Adult; Aortic Valve; Aortic Valve Insufficiency; Appetite Depressants; Blood Pressure; Delayed-Actio | 1998 |
Pharmacologic induction of weight loss to treat type 2 diabetes.
Topics: Appetite Depressants; Behavior Therapy; Blood Glucose; Blood Pressure; Diabetes Mellitus; Diabetes M | 1999 |
Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
Topics: Adrenergic Agents; Adult; Appetite Depressants; Body Mass Index; Double-Blind Method; Echocardiograp | 1999 |
Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.
Topics: Adult; Aged; Aortic Valve; Aortic Valve Insufficiency; Appetite Depressants; Blood Flow Velocity; De | 1999 |
Initial weight loss as a predictor of response to obesity drugs.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Drug Therapy, Combination; Female; Fenfluramine; H | 1999 |
Changes in energy expenditure and substrate oxidation resulting from weight loss in obese men and women: is there an important contribution of leptin?
Topics: Adult; Basal Metabolism; Blood Glucose; Body Mass Index; Diet, Reducing; Energy Intake; Energy Metab | 2000 |
d-Fenfluramine selectively suppresses carbohydrate snacking by obese subjects.
Topics: Adult; Appetite Depressants; Dietary Carbohydrates; Dietary Proteins; Eating; Energy Intake; Feeding | 1985 |
Letter: Peripheral effects of anorectic drugs.
Topics: Body Weight; Female; Fenfluramine; Humans; Male; Obesity; Placebos | 1976 |
Dreaming, fenfluramine, and vitamin C.
Topics: Ascorbic Acid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dreams; Female; Fenfluram | 1977 |
Metabolic effects of fenfluramine in obese diabetics.
Topics: Aged; Blood Glucose; Body Weight; Cholesterol; Clinical Trials as Topic; Diabetes Mellitus; Female; | 1977 |
[Clinical trial of a new long-acting fenfluramine in the treatment of obesity].
Topics: Adolescent; Adult; Clinical Trials as Topic; Delayed-Action Preparations; Female; Fenfluramine; Huma | 1978 |
Fenfluramine, vitamin C and weight loss.
Topics: Administration, Oral; Ascorbic Acid; Body Weight; Clinical Trials as Topic; Diet, Reducing; Double-B | 1978 |
The effect of fenfluramine on obese, maturity-onset diabetic patients.
Topics: Aged; Blood Glucose; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mellitus; Double-Bl | 1979 |
Clinical aspects of the treatment of obesity by drugs: a review.
Topics: Amphetamines; Appetite Depressants; Clinical Trials as Topic; Diethylpropion; Drug Tolerance; Female | 1979 |
[Treatment of obesity with fenfluramine (Ponderal) in general practice].
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Fenfluramine; Humans; Male; Obesity; P | 1979 |
Plasma fenfluramine levels, weight loss, and side effects.
Topics: Adult; Aged; Body Weight; Female; Fenfluramine; Humans; Middle Aged; Norfenfluramine; Obesity | 1977 |
Metabolic effects of fenfluramine--a double-blind study.
Topics: Adult; Basal Metabolism; Body Weight; Clinical Trials as Topic; Diet, Reducing; Female; Fenfluramine | 1975 |
Prolonged-action fenfluramine in non-diabetic patients with refractory obesity.
Topics: Adolescent; Adult; Clinical Trials as Topic; Delayed-Action Preparations; Diet, Reducing; Female; Fe | 1975 |
Influence of a long acting preparation of fenfluramine on body weight, body composition and skinfold thickness in obese subjects.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Fenfluramine; Humans; Obesity | 1975 |
Therapeutic effect of fenfluramine in obese Nigerians--clinical, metabolic and hypotensive properties.
Topics: Clinical Trials as Topic; Female; Fenfluramine; Humans; Male; Nigeria; Obesity | 1975 |
A clinical trial of a new fenfluramine preparation (Ponderax PA).
Topics: Blood Pressure; Body Weight; Clinical Trials as Topic; Delayed-Action Preparations; Female; Fenflura | 1975 |
A comparison of the efficacy and acceptability of fenfluramine tablets (BP) and prolonged action capsules.
Topics: Blood Pressure; Body Weight; Clinical Trials as Topic; Delayed-Action Preparations; Female; Fenflura | 1975 |
The effect of fenfluramine on obesity and plasma lipids of patients with renal allografts.
Topics: Body Weight; Clinical Trials as Topic; Female; Fenfluramine; Humans; Hypercholesterolemia; Kidney Tr | 1975 |
Acceptability of prolonged release fenfluramine capsules in obese patients in general practice.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Fenfluramine; Humans; Obesity | 1975 |
Fenfluramine and methylcellulose in the treatment of obesity: the relationship between plasma drug concentrations and therapeutic efficacy.
Topics: Adolescent; Adult; Aged; Biological Availability; Clinical Trials as Topic; Diet, Reducing; Female; | 1975 |
Phenformin compared with fenfluramine in the treatment of obese diabetic patients.
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus; Female; Fenfluramine; Glucose Tolerance Te | 1976 |
Emotional symptomatology in obese patients treated with fenfluramine and dextroamphetamine.
Topics: Adult; Anxiety; Body Weight; Clinical Trials as Topic; Depression; Dextroamphetamine; Emotions; Fema | 1976 |
[Glucose tolerance, insulin and lipids after one week's administration of fenfluramine to overweight patients (author's transl)].
Topics: Adult; Blood Glucose; Body Weight; Cholesterol; Fatty Acids, Nonesterified; Fenfluramine; Glucose To | 1975 |
Anorectic effectiveness of differing dosage forms of fenfluramine.
Topics: Adolescent; Adult; Aged; Appetite; Blood Pressure; Body Weight; Clinical Trials as Topic; Dosage For | 1976 |
Behavioral and pharmacological treatments for obesity: an experimental comparison.
Topics: Adolescent; Adult; Behavior Therapy; Evaluation Studies as Topic; Exercise Therapy; Female; Fenflura | 1976 |
Prolonged action fenfluramine capsules versus fenfluramine tablets in general practice.
Topics: Adult; Clinical Trials as Topic; Delayed-Action Preparations; Fenfluramine; Humans; Male; Obesity; P | 1975 |
Prolonged action fenfluramine in general practice.
Topics: Adult; Clinical Trials as Topic; Delayed-Action Preparations; Female; Fenfluramine; Humans; Male; Mi | 1975 |
Hormonal and metabolic studies of the action of fenfluramine in normal man, obesity, acromegaly and diabetes mellitus.
Topics: Acromegaly; Adult; Aged; Blood Glucose; Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Fenfl | 1975 |
A trial of fenfluramine (PACaps) and diet in overweight diabetic patients.
Topics: Body Weight; Diabetes Mellitus; Diet, Reducing; Fenfluramine; Humans; Obesity | 1975 |
780SE in the management of disorders of lipid and glucose metabolism.
Topics: Adult; Aged; Diabetes Mellitus; Female; Fenfluramine; Humans; Hyperlipidemias; Male; Middle Aged; Ob | 1975 |
Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Diet, Reducing; Double-Blind Method; Energy Intake; Female; Fen | 1992 |
Benefit:risk consideration in long-term therapy with dexfenfluramine.
Topics: Fenfluramine; Humans; Obesity; Placebos; Risk Factors | 1992 |
Body weight evolution during dexfenfluramine treatment after initial weight control.
Topics: Adult; Body Weight; Diet, Reducing; Double-Blind Method; Energy Intake; Female; Fenfluramine; Humans | 1992 |
[Antidiabetic efficacy of benfluorex. Clinical data].
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Fenfluramine; Humans; Hypolipidemic A | 1992 |
Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study.
Topics: Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Fenfluramine; Follow-Up St | 1992 |
Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour.
Topics: Adult; Analysis of Variance; Cardiovascular Diseases; Feeding Behavior; Female; Fenfluramine; Humans | 1992 |
Effect of fenfluramine on serum T3, T4 and TSH levels in obesity.
Topics: Adult; Case-Control Studies; Diet, Reducing; Female; Fenfluramine; Humans; Obesity; Prospective Stud | 1992 |
[Changes in dietary intake of obese patients treated by diet associated with d-fenfluramine].
Topics: Adult; Diet, Reducing; Double-Blind Method; Female; Fenfluramine; Humans; Middle Aged; Obesity; Plac | 1992 |
Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.
Topics: Adult; Behavior Therapy; Blood Pressure; Body Weight; Diet, Reducing; Double-Blind Method; Exercise; | 1992 |
Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
Topics: Adult; Behavior Therapy; Blood Pressure; Combined Modality Therapy; Diet, Reducing; Drug Therapy, Co | 1992 |
Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine.
Topics: Adult; Blood Pressure; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fem | 1992 |
Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
Topics: Adult; Behavior Therapy; Body Weight; Diet, Reducing; Double-Blind Method; Drug Therapy, Combination | 1992 |
Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication.
Topics: Adult; Behavior Therapy; Body Weight; Diet, Reducing; Double-Blind Method; Drug Therapy, Combination | 1992 |
Long-term weight control study. VI. Individual participant response patterns.
Topics: Adult; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenflur | 1992 |
Long-term weight control study. VII (weeks 0 to 210). Serum lipid changes.
Topics: Adult; Behavior Therapy; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug | 1992 |
Long-term weight control study: conclusions.
Topics: Adult; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diet, Reducing; Drug Therapy, C | 1992 |
The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2 | 1992 |
Drug therapy after very-low-calorie diets.
Topics: Adult; Affect; Combined Modality Therapy; Diet, Reducing; Double-Blind Method; Energy Intake; Female | 1992 |
Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients.
Topics: Adult; Blood Pressure; Body Weight; Catecholamines; Double-Blind Method; Exercise; Female; Fenfluram | 1992 |
Clinical studies with d-fenfluramine.
Topics: Body Weight; Female; Fenfluramine; Humans; Obesity | 1992 |
Naloxone does not modify fenfluramine-induced prolactin increase in obese patients.
Topics: Adolescent; Adult; Female; Fenfluramine; Humans; Hypothalamus; Naloxone; Obesity; Prolactin; Single- | 1991 |
Weight gain and withdrawal symptoms after smoking cessation: a preventive intervention using d-fenfluramine.
Topics: Adult; Affect; Arousal; Double-Blind Method; Female; Fenfluramine; Food Preferences; Humans; Middle | 1991 |
Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Me | 1991 |
Haemodynamic, metabolic and endocrine effects of short-term dexfenfluramine treatment in young, obese women.
Topics: Adult; Blood Pressure; Body Composition; Body Constitution; Double-Blind Method; Endocrine Glands; E | 1991 |
Impaired growth hormone response to insulin-induced hypoglycaemia in obese patients: restoration blocked by ritanserin after fenfluramine administration.
Topics: Adult; Blood Glucose; Female; Fenfluramine; Growth Hormone; Humans; Hypoglycemia; Insulin; Middle Ag | 1990 |
Serotonergic control of TSH and PRL secretion in obese men.
Topics: Adult; Diet, Reducing; Fenfluramine; Humans; Hypothyroidism; Male; Obesity; Prolactin; Receptors, Se | 1990 |
[Clinical observations on the treatment of obese patients with dexfenfluramine].
Topics: Adult; Double-Blind Method; Female; Fenfluramine; Humans; Male; Obesity; Placebos; Randomized Contro | 1990 |
The effect of long-term dexfenfluramine treatment on 24-hour energy expenditure in man. A double-blind placebo controlled study.
Topics: Adult; Body Temperature; Body Weight; Calorimetry; Clinical Trials as Topic; Double-Blind Method; En | 1990 |
[Drug therapy of obesity--results of treatment with dexfenfluramine].
Topics: Adult; Female; Fenfluramine; Humans; Male; Middle Aged; Obesity; Weight Loss | 1990 |
International trial of long-term dexfenfluramine in obesity.
Topics: Adult; Aged; Double-Blind Method; Female; Fenfluramine; Humans; Male; Middle Aged; Multicenter Studi | 1989 |
Effects of benfluorex in obese patients with metabolic disorders.
Topics: Blood Glucose; Female; Fenfluramine; Hormones; Humans; Hypolipidemic Agents; Lipids; Male; Metabolic | 1989 |
[Isomeride and treatment of overweight].
Topics: Double-Blind Method; Europe; Fenfluramine; Humans; International Cooperation; Multicenter Studies as | 1989 |
A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Female; Fenfluramine; Hu | 1988 |
Efficacy and safety of dexfenfluramine in obese patients: a multicenter study.
Topics: Adult; Blood Cell Count; Blood Pressure; Double-Blind Method; Female; Fenfluramine; Humans; Male; Mu | 1988 |
Effect of 6 months therapy with dexfenfluramine in obese patients: studies in the United Kingdom.
Topics: Clinical Trials as Topic; Double-Blind Method; Fenfluramine; Humans; Obesity; Time Factors; United K | 1988 |
Effects of fenfluramine in hypertriglyceridemic obese subjects.
Topics: Adult; Apoproteins; Clinical Trials as Topic; Double-Blind Method; Female; Fenfluramine; Humans; Hyp | 1988 |
Effect of fenfluramine on insulin/growth hormone ratio in obese subjects.
Topics: Adult; Arginine; Female; Fenfluramine; Growth Hormone; Humans; Insulin; Middle Aged; Obesity | 1988 |
Behavioural management of obesity.
Topics: Adolescent; Adult; Behavior Therapy; Child; Clinical Trials as Topic; Cognition; Combined Modality T | 1985 |
A controlled investigation of the "glycolyptic" action of fenfluramine.
Topics: Adult; Aged; Clinical Trials as Topic; Diet, Reducing; Female; Fenfluramine; Glucose; Glycogen; Glyc | 1972 |
Fenfluramine in the treatment of obesity.
Topics: Adult; Appetite Depressants; Body Weight; Clinical Trials as Topic; Constipation; Dextroamphetamine; | 1973 |
Effects of caloric restriction and fenfluramine on weight loss and personality profiles of patients with long standing obesity.
Topics: Adolescent; Adult; Aged; Body Weight; Clinical Trials as Topic; Diet, Reducing; Drug Tolerance; Feed | 1973 |
Fenfluramine in obese patients on various antihypertensive drugs. Double-blind controlled trial.
Topics: Antihypertensive Agents; Appetite Depressants; Blood Glucose; Blood Pressure; Body Weight; Cholester | 1969 |
Comparison of fenfluramine and metformin in treatment of obesity.
Topics: Adult; Appetite Depressants; Body Weight; Clinical Trials as Topic; Female; Fenfluramine; Fluorine; | 1970 |
Circulatory effects of fenfluramine in obese hypertensive patients.
Topics: Blood Pressure; Body Weight; Cardiac Output; Clinical Trials as Topic; Female; Fenfluramine; Heart R | 1974 |
A trial of fenfluramine in children with obesity associated with reduced muscle activity.
Topics: Adolescent; Age Factors; Blood Glucose; Cerebral Palsy; Child; Cholesterol; Clinical Trials as Topic | 1972 |
A double-blind clinical trial of fenfluramine.
Topics: Appetite Regulation; Blood Pressure; Body Height; Body Weight; Clinical Trials as Topic; Diarrhea; F | 1972 |
[Fenfluramine-treatment of neuroleptic-induced obesity].
Topics: Clinical Trials as Topic; Female; Fenfluramine; Humans; Obesity; Placebos; Tranquilizing Agents | 1972 |
Double-blind cross-over study of fenfluramine (Ponderax) in obesity.
Topics: Adult; Clinical Trials as Topic; Female; Fenfluramine; Humans; Male; Middle Aged; Obesity; Placebos | 1972 |
A comparative trial of different regimens of fenfluramine and phentermine in obesity.
Topics: Adult; Appetite Depressants; Clinical Trials as Topic; Diet Therapy; Female; Fenfluramine; Humans; M | 1973 |
A double-blind clinical trial of fenfluramine in the treatment of obesity.
Topics: Adolescent; Adult; Age Factors; Body Weight; Child; Clinical Trials as Topic; Female; Fenfluramine; | 1973 |
Treatment of obesity with fenfluramine.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Clinical Trials as Topic | 1973 |
[The effect of Ponderal in patients with refractory overweight].
Topics: Administration, Oral; Adolescent; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Depression, | 1973 |
[The therapeutic effect of Fenfluramine on body weight in overweight patients. A controlled clinical study].
Topics: Adolescent; Adult; Blood Pressure; Clinical Trials as Topic; Constipation; Depression, Chemical; Dia | 1973 |
Fenfluramine in corticosteroid-induced obesity.
Topics: Adult; Appetite; Asthma; Blood Pressure; Body Weight; Chronic Disease; Clinical Trials as Topic; Fem | 1972 |
[Treatment of obesity with fenfluramine (Ponderal)].
Topics: Adolescent; Adult; Blood Glucose; Body Weight; Cholesterol; Clinical Trials as Topic; Depression, Ch | 1973 |
[Effectiveness of fenfluramine as an aid in diet therapy of obesity].
Topics: Clinical Trials as Topic; Diet Therapy; Fenfluramine; Humans; Obesity | 1972 |
The metabolic effects, and the composition of the tissue lost, in weight reduction by obese patients on treatment with fenfluramine.
Topics: Adipose Tissue; Adult; Body Composition; Body Weight; Clinical Trials as Topic; Densitometry; Diet, | 1973 |
Fenfluramine in the management of obesity.
Topics: Adult; Aged; Appetite; Clinical Trials as Topic; Female; Fenfluramine; Humans; Male; Middle Aged; Ob | 1973 |
Comparison of a new anorectic agent AN 448 with fenfluramine in the treatment of refractory obesity.
Topics: Adult; Appetite Depressants; Body Weight; Clinical Trials as Topic; Female; Fenfluramine; Humans; Im | 1974 |
Evaluation of three anorexiants. Clortermine hydrochloride (voranil), fenfluramine hydrochloride (pondimin), and mazindol (sanorex).
Topics: Adolescent; Adult; Age Factors; Appetite Depressants; Clinical Trials as Topic; Depression; Diet, Re | 1974 |
The effect of a low-calorie diet with and without fenfluramine, and fenfluramine alone on the glucose tolerance and insulin secretion of overweight non-diabetics.
Topics: Adult; Diet, Reducing; Female; Fenfluramine; Glucose Tolerance Test; Humans; Insulin; Insulin Secret | 1973 |
The effect of a low-calorie diet with and without fenfluramine on the glucose tolerance and insulin secretion of obese maturity-onset diabetics.
Topics: Adult; Aged; Diabetes Mellitus; Diet, Reducing; Fenfluramine; Glucose Tolerance Test; Humans; Insuli | 1973 |
Fenfluramine (Ponderax) in the treatment of obese psychiatric out-patients.
Topics: Anxiety Disorders; Appetite Depressants; Body Weight; Clinical Trials as Topic; Depression; Diarrhea | 1969 |
A comparative trial of fenfluramine and diethylpropion inbesity.
Topics: Adult; Aged; Appetite Depressants; Clinical Trials as Topic; Diethylpropion; Female; Fenfluramine; F | 1970 |
A comparative trial of fenfluramine and diethylpropion in obese, hypertensive patients.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Clinical Trials as Topic; Diethylpropion; Female; | 1971 |
[Hypoglycemic action of fenfluramine in obese diabetics].
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus; Female; Fenfluramine; Humans; Hypoglycemic | 1971 |
A clinical trial of fenfluramine in obese children.
Topics: Adolescent; Appetite Depressants; Child; Child, Preschool; Clinical Trials as Topic; Female; Fenflur | 1967 |
A collaborative investigation of fenfluramine. Anorexigenic with sedative properties.
Topics: Adult; Appetite Depressants; Body Weight; Clinical Trials as Topic; Female; Fenfluramine; Fluorine; | 1970 |
Withdrawal depression in obese patients after fenfluramine treatment.
Topics: Adult; Appetite; Appetite Depressants; Depression; Female; Fenfluramine; Humans; Middle Aged; Obesit | 1972 |
Comparison of fenfluramine (with ad libitum food intake) with 1,000 calorie diet in obesity.
Topics: Adolescent; Adult; Aged; Diet, Reducing; Evaluation Studies as Topic; Female; Fenfluramine; Humans; | 1972 |
A clinical trial of fenfluramine.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Child; Clinical Trials as Topic; Diet, Reducing; Ethy | 1965 |
Treatment of refractory obesity with fenfluramine.
Topics: Adult; Aged; Appetite Depressants; Clinical Trials as Topic; Diarrhea; Female; Fenfluramine; Humans; | 1966 |
Hypotensive effect of fenfluramine in the treatment of obesity.
Topics: Adult; Aged; Appetite Depressants; Female; Fenfluramine; Fluorine; Humans; Hypertension; Male; Middl | 1971 |
Weight reduction in obesity.
Topics: Appetite Depressants; Female; Fenfluramine; Fluorine; Humans; Metformin; Obesity; Phenethylamines | 1969 |
[Experience with the appetite depressant, fenfluramine hydrochloride, in adiposity].
Topics: Adolescent; Adult; Aged; Appetite Depressants; Child; Diabetes Mellitus; Diet, Reducing; Female; Fen | 1969 |
Fenfluramine in the treatment of obesity.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Female; Fenfluramine; Humans; Male; Middle Aged; Obes | 1966 |
291 other studies available for fenfluramine and Obesity
| Article | Year |
|---|---|
Weight Loss Supplement-Induced Pulmonary Hypertension: A Decades Delayed Presentation of Fenfluramine-Phentermine.
Topics: Fenfluramine; Humans; Hypertension, Pulmonary; Obesity; Phentermine; Weight Loss | 2023 |
Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth.
Topics: Adult; Child; Epilepsies, Myoclonic; Fenfluramine; Humans; Obesity; Seizures; Spasms, Infantile | 2021 |
Frequency of drug-induced valvular heart disease in patients previously exposd to benfluorex: a multicentre prospective study.
Topics: Analysis of Variance; Aortic Valve Insufficiency; Appetite Depressants; Case-Control Studies; Diabet | 2013 |
5-HT obesity medication efficacy via POMC activation is maintained during aging.
Topics: Aging; Animals; Female; Fenfluramine; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesit | 2014 |
Fatal dynamic mitral regurgitation as a presentation of benfluorex-Induced valvular heart toxicity.
Topics: Aged; Appetite Depressants; Autopsy; Echocardiography; Fatal Outcome; Fenfluramine; Heart Valve Pros | 2015 |
Is new hope on the horizon for obesity?
Topics: Anti-Obesity Agents; Bridged Bicyclo Compounds, Heterocyclic; Caloric Restriction; Fenfluramine; Hum | 2008 |
Brain serotonin, psychoactive drugs, and effects on reproduction.
Topics: Affect; Amphetamine-Related Disorders; Animals; Biological Clocks; Brain; Cognition Disorders; Depre | 2009 |
Restrictive organic mitral regurgitation associated with benfluorex therapy.
Topics: Aged; Appetite Depressants; Body Mass Index; Cardiomyopathy, Restrictive; Diabetes Mellitus; Drug Th | 2010 |
Drug management of obesity--efficacy versus safety.
Topics: Anti-Obesity Agents; Benzazepines; Contraindications; Cyclobutanes; Drug Approval; Fenfluramine; Hum | 2010 |
MR molecular imaging of aortic angiogenesis.
Topics: Animals; Aorta; Appetite Depressants; Atherosclerosis; Body Weight; Cholesterol; Disease Models, Ani | 2010 |
Progressive ratio responding in an obese mouse model: Effects of fenfluramine.
Topics: Animals; Appetite Depressants; Appetitive Behavior; Conditioning, Operant; Extinction, Psychological | 2010 |
Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry.
Topics: Appetite Depressants; Body Mass Index; Comorbidity; Dose-Response Relationship, Drug; Echocardiograp | 2011 |
[What were the indications for the Mediator in 1979?].
Topics: Anxiety; Appetite Depressants; Diabetes Mellitus, Type 2; Fenfluramine; France; Heart Valve Diseases | 2011 |
[The French are wary of their drugs].
Topics: Appetite Depressants; Body Mass Index; Cause of Death; Drugs, Generic; Fenfluramine; France; Heart V | 2011 |
Valvular heart disease with the use of fenfluramine-phentermine.
Topics: Anti-Obesity Agents; Drug Combinations; Echocardiography, Doppler, Color; Female; Fenfluramine; Gast | 2011 |
Fen-Phen-noumenon: A mass tort litigation and settlement about to come and go.
Topics: Appetite Depressants; Central Nervous System Stimulants; Fenfluramine; Heart Valve Diseases; Humans; | 2002 |
Morphology of anorexigen-associated valve disease by transthoracic and transesophageal echocardiography.
Topics: Adult; Aortic Valve; Appetite Depressants; Body Mass Index; Dexfenfluramine; Drug Combinations; Echo | 2002 |
[Electron microscope observation on effect of kudingcha inspissation tea on small intestine villus in the adiposity rats].
Topics: Adipocytes; Animals; Animals, Newborn; Anti-Obesity Agents; Appetite Depressants; Drugs, Chinese Her | 1999 |
Greater than predicted decrease in energy expenditure during exercise after body weight loss in obese men.
Topics: Adult; Aged; Analysis of Variance; Body Composition; Energy Metabolism; Exercise; Female; Fenflurami | 2003 |
A PRELIMINARY TRIAL OF FENFLURAMINE IN GENERAL PRACTICE.
Topics: Appetite Depressants; Biomedical Research; Drug Therapy; Family Practice; Fenfluramine; Obesity; Pla | 1965 |
Taking things to heart.
Topics: Appetite Depressants; Dexfenfluramine; Drug Combinations; Fenfluramine; Heart Valve Diseases; Humans | 2004 |
Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Dexfenfluramine; Female; Fenfluramine; Humans; Life Sty | 2004 |
Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice.
Topics: Animals; Appetite; Appetite Depressants; Dietary Fats; Eating; Energy Metabolism; Fenfluramine; Food | 2005 |
Primary pulmonary arterial hypertension presenting as diffuse micronodules on CT.
Topics: Adult; Appetite Depressants; Asthma; Drug Combinations; Female; Fenfluramine; Humans; Hypertension, | 2004 |
Pharmacotherapy for childhood obesity? Maybe for some.
Topics: Adolescent; Fenfluramine; Humans; Obesity; Selective Serotonin Reuptake Inhibitors | 1994 |
Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.
Topics: Adult; Appetite Depressants; Body Mass Index; Drug Therapy, Combination; Fenfluramine; Fluoxetine; H | 2007 |
Spontaneous coronary artery dissection in a woman on fenfluramine.
Topics: Adult; Aortic Dissection; Coronary Aneurysm; Coronary Angiography; Diagnosis, Differential; Electroc | 2007 |
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases.
Topics: Adult; Age Distribution; Analysis of Variance; Appetite Depressants; Confidence Intervals; Female; F | 2008 |
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases.
Topics: Adult; Age Distribution; Analysis of Variance; Appetite Depressants; Confidence Intervals; Female; F | 2008 |
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases.
Topics: Adult; Age Distribution; Analysis of Variance; Appetite Depressants; Confidence Intervals; Female; F | 2008 |
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases.
Topics: Adult; Age Distribution; Analysis of Variance; Appetite Depressants; Confidence Intervals; Female; F | 2008 |
Synergistic impairment of glucose homeostasis in ob/ob mice lacking functional serotonin 2C receptors.
Topics: Animals; Diabetes Mellitus; Disease Models, Animal; Drinking; Eating; Female; Fenfluramine; Glucose; | 2008 |
Fenfluramine and brain transmitters in the obese Zucker rat.
Topics: Animals; Body Weight; Brain Chemistry; Catecholamines; Dopamine; Feeding Behavior; Female; Fenfluram | 1984 |
d-Fenfluramine selectively decreases carbohydrate but not protein intake in obese subjects.
Topics: Animals; Appetite; Dietary Carbohydrates; Dietary Proteins; Eating; Feeding Behavior; Fenfluramine; | 1984 |
Fenfluramine lowers plasma norepinephrine in overweight subjects.
Topics: Adult; Blood Pressure; Female; Fenfluramine; Heart Rate; Humans; Male; Norepinephrine; Obesity; Post | 1983 |
Pulmonary hypertension and fenfluramine.
Topics: Adult; Electrocardiography; Female; Fenfluramine; Humans; Hypertension, Pulmonary; Middle Aged; Obes | 1981 |
Obesity drug, genetic studies renew hope for autism therapy.
Topics: Autistic Disorder; Child; Child, Preschool; Fenfluramine; Genes; Humans; Male; Obesity; Serotonin | 1983 |
Appetite depressants: weights and measures.
Topics: Amphetamines; Appetite Depressants; Fenfluramine; Humans; Mazindol; Obesity | 1981 |
Fenfluramine in management of obese diabetics.
Topics: Adult; Blood Pressure; Body Weight; Diabetes Mellitus; Drug Synergism; Female; Fenfluramine; Humans; | 1980 |
[Activity of fenfluramine in obese subjects. Relation between dosage, plasma concentration of the drug and its effect on weight loss].
Topics: Adult; Aged; Body Weight; Dose-Response Relationship, Drug; Female; Fenfluramine; Humans; Male; Midd | 1982 |
[Chronotherapy of obesity. I. Effect of fenfluramine on the decrease of adipose mass in the obese, in relation to the time of administration].
Topics: Adipose Tissue; Adult; Body Weight; Drug Administration Schedule; Female; Fenfluramine; Humans; Male | 1982 |
[Chronotherapy of obesity. II. Variations in eating behavior in the obese after fenfluramine treatment in relation to time of administration].
Topics: Adult; Appetite; Drug Administration Schedule; Feeding Behavior; Female; Fenfluramine; Humans; Kinet | 1982 |
What to tell patients about weight-loss methods. 2. Drugs.
Topics: Amphetamines; Appetite Depressants; Diethylpropion; Diuretics; Fenfluramine; Humans; Obesity; Phenyl | 1982 |
Plasma fenfluramine levels, weight loss and side effects: a failure to find a relationship.
Topics: Adult; Aged; Behavior Therapy; Body Weight; Female; Fenfluramine; Humans; Middle Aged; Obesity | 1982 |
[A case of chronic pulmonary hypertension after fenfluramine intake].
Topics: Chronic Disease; Female; Fenfluramine; Humans; Hypertension, Pulmonary; Middle Aged; Nifedipine; Obe | 1982 |
[Fenfluramin in the therapy of obesity (author's transl)].
Topics: Adult; Fenfluramine; Humans; Middle Aged; Obesity | 1981 |
Differential changes in plasma high-density lipoprotein-cholesterol levels in obese men and women during weight reduction.
Topics: Adult; Body Weight; Cholesterol; Female; Fenfluramine; Humans; Lipoproteins; Lipoproteins, HDL; Lipo | 1981 |
Couples training, pharmacotherapy, and behavior therapy in the treatment of obesity.
Topics: Adult; Behavior Therapy; Body Weight; Female; Fenfluramine; Humans; Male; Marital Therapy; Obesity | 1981 |
Effects of d-amphetamine and fenfluramine on feeding pattens and activity of obese and lean Zucker rats.
Topics: Animals; Dextroamphetamine; Diet; Drinking Behavior; Feeding Behavior; Fenfluramine; Male; Motor Act | 1980 |
Fenfluramine potentiation of antihypertensive effects of thiazides.
Topics: Antihypertensive Agents; Blood Pressure; Body Weight; Drug Synergism; Drug Therapy, Combination; Fen | 1980 |
The effect of fenfluramine on weight loss during restricted dietary regimes.
Topics: Body Weight; Female; Fenfluramine; Humans; Male; Norfenfluramine; Obesity | 1980 |
[Pulmonary hypertension following use of fenfluramine for obesity].
Topics: Adult; Female; Fenfluramine; Heart Function Tests; Humans; Hypertension, Pulmonary; Obesity; Pulmona | 1994 |
Major depression during dexfenfluramine treatment.
Topics: Depressive Disorder; Fenfluramine; Humans; Male; Middle Aged; Obesity | 1994 |
Long-term administration of dexfenfluramine to genetically obese (ob/ob) and lean mice: body weight and brain serotonin changes.
Topics: Animals; Blood Glucose; Body Weight; Brain Chemistry; Corticosterone; Dietary Fats; Female; Fenflura | 1994 |
The role of dexfenfluramine in the regulation of energy balance. Introduction.
Topics: Adolescent; Adult; Animals; Energy Metabolism; Fatty Acids, Nonesterified; Female; Fenfluramine; Hum | 1995 |
Chronobiometric identification of disorders of hunger sensation in essential obesity: therapeutic effects of dexfenfluramine.
Topics: Adult; Circadian Rhythm; Female; Fenfluramine; Humans; Hunger; Male; Middle Aged; Obesity | 1995 |
Successful appetite suppression therapy with fenfluramine and phentermine in the obese diabetic transplant patient.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetic Nephropathies; Diet, Reducing; Drug Therapy, | 1995 |
Report on the NIH Workshop on Pharmacologic Treatment of Obesity.
Topics: Animals; Drug Therapy, Combination; Fenfluramine; Humans; Obesity; Phentermine | 1994 |
Obesity drug renews toxicity debate.
Topics: Animals; Drug Approval; Fenfluramine; Humans; Nervous System Diseases; Obesity; United States; Unite | 1994 |
Fluoxetine (Prozac) and other drugs for treatment of obesity.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Fenfluramine; Fluoxetine; Humans; Obesity; Phen | 1994 |
Combined dopamine and serotonin agonists: a synergistic approach to alcoholism and other addictive behaviors.
Topics: Adult; Alcohol Deterrents; Alcoholism; Dopamine Agents; Drug Synergism; Female; Fenfluramine; Humans | 1993 |
d-fenfluramine and cognitive therapy in bulimia nervosa.
Topics: Body Weight; Bulimia; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Fenfluramine; | 1993 |
Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants.
Topics: Albuterol; Animals; Appetite Depressants; Cyclohexanes; Dextroamphetamine; Drug Tolerance; Eating; E | 1993 |
Turnover and oxidation rates of plasma-free fatty acids in obese patients treated with dexfenfluramine.
Topics: Adult; Drug Administration Schedule; Energy Metabolism; Fatty Acids; Female; Fenfluramine; Humans; M | 1993 |
d-fenfluramine in a rat model of dietary fat-induced obesity.
Topics: Animals; Dietary Fats; Disease Models, Animal; Eating; Fenfluramine; Guanosine Diphosphate; Hypothal | 1993 |
Should drugs be used for treating obese children?
Topics: Adolescent; Child; Fenfluramine; Humans; Obesity | 1993 |
Is it dexfenfluramine or weight loss that reduces blood pressure and noradrenergic activity in obese patients?
Topics: Blood Pressure; Body Weight; Fenfluramine; Humans; Hypertension; Norepinephrine; Obesity | 1993 |
Dexfenfluramine influences dietary compliance and eating behavior, but dietary instruction may overrule its effect on food selection in obese subjects.
Topics: Adult; Diet, Reducing; Dietary Fats; Dietary Proteins; Eating; Energy Intake; Feeding Behavior; Fema | 1993 |
[Is it possible to obtain a reduction of body weight exclusively via a loss in fat mass? Experience with d-fenfluramine].
Topics: Adipose Tissue; Adult; Anthropometry; Body Composition; Combined Modality Therapy; Diet, Reducing; D | 1993 |
Smoking cessation in a patient being treated with fenfluramine plus phentermine for simple obesity.
Topics: Adult; Alcohol Drinking; Comorbidity; Drug Therapy, Combination; Fenfluramine; Humans; Male; Obesity | 1996 |
Long-term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss.
Topics: Adult; Amino Acids; Appetite Depressants; Dietary Fats; Dietary Proteins; Female; Fenfluramine; Food | 1996 |
[Obesity: physiology and possibilities for treatment].
Topics: Adult; Animals; Appetite Depressants; Developed Countries; Energy Intake; Female; Fenfluramine; Huma | 1995 |
From the Food and Drug Administration.
Topics: Advertising; AIDS Serodiagnosis; Appetite Depressants; Consumer Product Safety; Fenfluramine; HIV In | 1996 |
Pharmacotherapy for obesity -- do the benefits outweigh the risks?
Topics: Appetite Depressants; Fenfluramine; Humans; Hypertension, Pulmonary; Obesity | 1996 |
Treatment for obesity.
Topics: Adrenergic Uptake Inhibitors; Appetite Depressants; Combined Modality Therapy; Fenfluramine; Humans; | 1996 |
Dexfenfluramine for obesity.
Topics: Clinical Trials as Topic; Fenfluramine; Humans; Obesity | 1996 |
Somatometric and hormonal effects of dexfenfluramine.
Topics: Appetite Depressants; Body Weight; Energy Intake; Female; Fenfluramine; Growth Hormone; Hormones; Hu | 1995 |
Energy expenditure and substrate oxidation rates of obese rats during a 12-day treatment with dexfenfluramine.
Topics: Amino Acids; Animals; Blood Glucose; Body Weight; Calorimetry, Indirect; Dose-Response Relationship, | 1996 |
[The treatment of the obese non-insulin-dependent patient with d-fenfluramine].
Topics: Adult; Aged; Appetite Depressants; Chronic Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dr | 1996 |
Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM.
Topics: Adipose Tissue; Adult; Appetite Depressants; Body Composition; Body Constitution; Body Mass Index; C | 1996 |
Editorials and conflicts of interest.
Topics: Appetite Depressants; Biomedical Research; Conflict of Interest; Disclosure; Editorial Policies; Fen | 1996 |
New agent for obesity management.
Topics: Appetite Depressants; Fenfluramine; Humans; Obesity | 1996 |
New agent for obesity management.
Topics: Appetite Depressants; Fenfluramine; Humans; Obesity; Phentermine | 1996 |
Conflicts of interest--editorialists respond.
Topics: Appetite Depressants; Biomedical Research; Conflict of Interest; Disclosure; Editorial Policies; Fen | 1996 |
Serotonergic agents in the treatment of hypothalamic obesity syndrome: a case report.
Topics: Adult; Body Weight; Brain Damage, Chronic; Dose-Response Relationship, Drug; Fenfluramine; Fluoxetin | 1996 |
Potential hazard of serotonin syndrome associated with dexfenfluramine hydrochloride (Redux)
Topics: Contraindications; Depressive Disorder; Drug Interactions; Fenfluramine; Humans; Obesity; Serotonin | 1996 |
Iowa patients want new anti-obesity drug.
Topics: Appetite Depressants; Diet, Reducing; Fenfluramine; Humans; Obesity; Patient Education as Topic; Sel | 1996 |
Metabolic indices in relation to body composition changes during weight loss on Dexfenfluramine in obese women from two South African ethnic groups.
Topics: Adipose Tissue; Adult; Anthropometry; Appetite Depressants; Black or African American; Black People; | 1996 |
Changes in energy metabolism and metabolite patterns of obese rats after application of dexfenfluramine.
Topics: Animals; Body Weight; Dose-Response Relationship, Drug; Eating; Energy Metabolism; Fenfluramine; Mal | 1996 |
Dexfenfluramine effect on ACTH and GH in obese subjects.
Topics: Adrenocorticotropic Hormone; Fenfluramine; Growth Hormone-Releasing Hormone; Human Growth Hormone; H | 1996 |
Effects of benfluorex on serum triacylglycerols and insulin sensitivity in the corpulent rat.
Topics: Animals; Body Weight; Disease Models, Animal; Eating; Female; Fenfluramine; Hypolipidemic Agents; In | 1996 |
New treatment for obesity: dexfenfluramine (Redux).
Topics: Appetite Depressants; Body Mass Index; Fenfluramine; Humans; Obesity; Patient Selection | 1996 |
Primary pulmonary hypertension and long-term use of appetite suppressants.
Topics: Adult; Appetite Depressants; Body Mass Index; Female; Fenfluramine; Humans; Hypertension, Pulmonary; | 1997 |
Appetite suppressants for obesity.
Topics: Appetite Depressants; Fenfluramine; Health Status; Humans; Obesity; Phentermine | 1997 |
Appetite-suppressant drugs and primary pulmonary hypertension.
Topics: Aminorex; Appetite Depressants; Fenfluramine; Humans; Hypertension, Pulmonary; Obesity | 1997 |
Fenfluramine and the cytochrome P450 system.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Fenfl | 1997 |
Dexfenfluramine.
Topics: Appetite Depressants; Fenfluramine; Humans; Obesity | 1997 |
The pharmacologic management of obesity.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Body Weight; Chronic Disease; Fen | 1997 |
Weighing benefits and risks of drug to treat obesity.
Topics: Appetite Depressants; Conflict of Interest; Fenfluramine; Humans; Hypertension; Obesity; Risk Assess | 1997 |
Drug to treat obesity: editorial writer responds.
Topics: Appetite Depressants; Conflict of Interest; Fenfluramine; Humans; Obesity | 1997 |
Obesity, dexfenfluramine, and pulmonary hypertension. A lesson not learned?
Topics: Appetite Depressants; Fenfluramine; Humans; Hypertension, Pulmonary; Obesity | 1997 |
Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM.
Topics: Adult; Biopsy; Confidence Intervals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Liver; Fema | 1997 |
Fenfluramine and phentermine.
Topics: Adult; Appetite Depressants; Female; Fenfluramine; Gastrointestinal Diseases; Humans; Obesity; Phent | 1997 |
Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity.
Topics: Appetite Depressants; Fenfluramine; Fluoxetine; Humans; Hypertension, Pulmonary; Obesity; Selective | 1997 |
Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats.
Topics: Animals; Arteriosclerosis; Fenfluramine; Hypolipidemic Agents; Insulin Resistance; Male; Obesity; Ra | 1997 |
Report links appetite suppressants with heart disease. FDA encourages reporting of like events.
Topics: Appetite Depressants; Drug Therapy, Combination; Fenfluramine; Heart Valve Diseases; Humans; Obesity | 1997 |
Cerebral hemorrhage in a patient taking fenfluramine and phentermine for obesity.
Topics: Appetite Depressants; Cerebral Hemorrhage; Drug Combinations; Female; Fenfluramine; Humans; Middle A | 1997 |
Diet pills redux.
Topics: Appetite Depressants; Drug Combinations; Female; Fenfluramine; Heart Valve Diseases; Humans; Hyperte | 1997 |
Obesity and the diet pill dilemma.
Topics: Appetite Depressants; Central Nervous System Stimulants; Fenfluramine; Humans; Obesity; Phentermine; | 1997 |
Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.
Topics: Animals; Cyclobutanes; Cyclohexanols; Eating; Fenfluramine; Fluoxetine; Male; Neurotransmitter Uptak | 1997 |
Three cases of comprehensive dietary therapy and pharmacotherapy of patients with complex obesity-related diseases.
Topics: Adult; Aged; Appetite Depressants; Diabetes Mellitus, Type 2; Diet, Reducing; Fatty Liver; Female; F | 1997 |
Obesity and an abnormal ECG.
Topics: Adult; Appetite Depressants; Drug Combinations; Electrocardiography; Female; Fenfluramine; Humans; H | 1997 |
Nutritional implications of xerostomia and rampant caries caused by serotonin reuptake inhibitors: a case study.
Topics: Adult; Antidepressive Agents; Dental Caries; Diet; Female; Fenfluramine; Fluoxetine; Humans; Obesity | 1997 |
Psychotic episode associated with dexfenfluramine.
Topics: Female; Fenfluramine; Humans; Male; Middle Aged; Obesity; Paranoid Disorders; Psychoses, Substance-I | 1997 |
Digital necrosis associated with dexfenfluramine.
Topics: Adult; Appetite Depressants; Diabetes Mellitus, Type 2; Fenfluramine; Fingers; Humans; Male; Necrosi | 1997 |
In memory of dexfenfluramine: R.I.P.
Topics: Appetite Depressants; Contraindications; Drug Therapy, Combination; Europe; Fenfluramine; Humans; Ob | 1997 |
The treatment of obesity with drugs.
Topics: Appetite Depressants; Drug Combinations; Female; Fenfluramine; Heart Valve Diseases; Humans; Hyperte | 1998 |
[Drug-clinics. The hue and cry over central appetite suppressants!].
Topics: Adrenergic Agents; Adult; Amphetamines; Appetite; Appetite Depressants; Female; Fenfluramine; Heart | 1997 |
Long-term drug treatment of obesity in a private practice setting.
Topics: Adolescent; Adult; Appetite Depressants; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight | 1997 |
Valve disease and diet pills--where do we stand?
Topics: Adult; Aged; Aged, 80 and over; Appetite Depressants; Dopamine Agents; Drug Therapy, Combination; Ec | 1998 |
The hope and the hazards of using compliance data in randomized controlled trials.
Topics: Appetite Depressants; Data Interpretation, Statistical; Double-Blind Method; Fenfluramine; Follow-Up | 1998 |
Delirium with manic symptoms induced by diet pills.
Topics: Adolescent; Bipolar Disorder; Delirium; Drug Therapy, Combination; Female; Fenfluramine; Humans; Mid | 1998 |
Aminorex, dexfenfluramine, and primary pulmonary hypertension.
Topics: Adult; Aminorex; Appetite Depressants; Europe; Female; Fenfluramine; Humans; Hypertension, Pulmonary | 1998 |
Improvement of insulin sensitivity and cardiovascular outcomes in the JCR:LA-cp rat by D-fenfluramine.
Topics: Acetylcholine; Animals; Aorta; Aorta, Thoracic; Aortic Diseases; Appetite Depressants; Arteriosclero | 1998 |
The fen-phen finale: a study of weight loss and valvular heart disease.
Topics: Adult; Affect; Appetite; Behavior Therapy; Drug Therapy, Combination; Echocardiography, Doppler; Fem | 1998 |
Bipolar depression associated with fenfluramine and phentermine.
Topics: Adult; Appetite Depressants; Bipolar Disorder; Drug Therapy, Combination; Female; Fenfluramine; Huma | 1998 |
Appetite-suppressant drugs and the risk of primary pulmonary hypertension?
Topics: Appetite Depressants; Body Mass Index; Female; Fenfluramine; Humans; Hypertension, Pulmonary; Incide | 1997 |
The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
Topics: Adult; Aortic Valve Insufficiency; Appetite Depressants; Case-Control Studies; Cross-Sectional Studi | 1998 |
A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
Topics: Adult; Aged; Aortic Valve Insufficiency; Appetite Depressants; Case-Control Studies; Drug Combinatio | 1998 |
Appetite suppressants and valvular heart disease.
Topics: Appetite Depressants; Drug Combinations; Fenfluramine; Heart Valve Diseases; Humans; Obesity; Phente | 1998 |
Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment.
Topics: Adult; Appetite Depressants; Drug Combinations; Female; Fenfluramine; Heart Valve Diseases; Humans; | 1998 |
[Urticaria and anaphylactic shock from benfluorex. Two case reports].
Topics: Adverse Drug Reaction Reporting Systems; Anaphylaxis; Appetite Depressants; Female; Fenfluramine; Fr | 1998 |
Diet-drug debacle.
Topics: Appetite Depressants; Dexfenfluramine; Fenfluramine; Heart Valve Diseases; Humans; Obesity; United S | 1998 |
Studies confirm link between fen-phen and heart-valve disease.
Topics: Appetite Depressants; Cyclobutanes; Dexfenfluramine; Drug Combinations; Fenfluramine; Heart Valve Di | 1998 |
Appetite-suppressant drugs and valvular heart disease.
Topics: Appetite Depressants; Bias; Dexfenfluramine; Fenfluramine; Heart Valve Diseases; Humans; Obesity; Od | 1999 |
After fen-phen.
Topics: Antidepressive Agents, Second-Generation; Appetite Depressants; Consumer Product Safety; Fenfluramin | 1997 |
Severe heart valve disease on appetite suppressants.
Topics: Adult; Appetite Depressants; Case-Control Studies; Diethylpropion; Drug Approval; Drug Combinations; | 1998 |
Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss.
Topics: Adult; Circadian Rhythm; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Combinat | 1999 |
[Study on effects of Codonopsis eupolyphaga anti-obesity powder in mice with nutritive obesity].
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Cholesterol; Drugs, Chinese Herba | 1997 |
Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke.
Topics: Aged; Appetite Depressants; Body Mass Index; Case-Control Studies; Cerebrovascular Disorders; Cohort | 1999 |
Valvular heart disease in fenfluramine- phentermine-treated patients: a comparison with control patients.
Topics: Appetite Depressants; Body Mass Index; Diet, Reducing; Drug Combinations; Echocardiography; Female; | 1999 |
Anorectic therapy and valvular heart disease: a reappraisal.
Topics: Appetite Depressants; Fenfluramine; Heart Valve Diseases; Heart Valves; Humans; Obesity; Phentermine | 1999 |
Physical activity and low-fat diet: is it enough to maintain weight stability in the reduced-obese individual following weight loss by drug therapy and energy restriction?
Topics: Adult; Appetite Depressants; Body Mass Index; Calorimetry, Indirect; Cohort Studies; Diet, Fat-Restr | 1999 |
Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
Topics: Aortic Valve Insufficiency; Appetite Depressants; Body Mass Index; Counseling; Dexfenfluramine; Drug | 1999 |
Heart valve lesions in patients treated with appetite suppressants.
Topics: Aortic Valve Insufficiency; Appetite Depressants; Dexfenfluramine; Echocardiography; Female; Fenflur | 1999 |
Synergistic anorectic effect of dehydroepiandrosterone and d-Fenfluramine on the obese Zucker rat.
Topics: Analysis of Variance; Animals; Appetite; Appetite Depressants; Dehydroepiandrosterone; Drug Synergis | 1999 |
Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters.
Topics: Adult; Appetite Depressants; Depression; Eating; Feeding and Eating Disorders; Female; Fenfluramine; | 1999 |
Pharmaceutical cost savings of treating obesity with weight loss medications.
Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug | 1999 |
Metabolic fitness in active reduced-obese individuals.
Topics: Adult; Basal Metabolism; Cholesterol, HDL; Cohort Studies; Diet, Reducing; Energy Intake; Energy Met | 1999 |
The fen-phen controversy: is regression another piece of the puzzle?
Topics: Appetite Depressants; Fenfluramine; Heart Valve Diseases; Humans; Obesity; Phentermine | 1999 |
Dehydroepiandrosterone (DHEA) decreases open-field spontaneous activity of Zucker rats.
Topics: Animals; Appetite Depressants; Brain Chemistry; Dehydroepiandrosterone; Depression, Chemical; Diet; | 1999 |
Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
Topics: Aortic Valve Insufficiency; Appetite Depressants; Body Mass Index; Dexfenfluramine; Echocardiography | 2000 |
Anorectic-induced valvulopathy.
Topics: Appetite Depressants; Fenfluramine; Heart Valve Diseases; Humans; Obesity; Phentermine; Time Factors | 2000 |
Was the danger of diet pills overstated?
Topics: Appetite Depressants; Drug Combinations; Fenfluramine; Heart Valve Diseases; Humans; Obesity; Phente | 2000 |
Fen-phen manufacturers, not physicians, are liable.
Topics: Appetite Depressants; Drug Combinations; Drug Industry; Fenfluramine; Heart Valve Diseases; Humans; | 2000 |
[Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants].
Topics: Aged; Appetite Depressants; Drug Therapy, Combination; Female; Fenfluramine; Heart Valve Diseases; H | 1998 |
Appetite after weight loss by energy restriction and a low-fat diet-exercise follow-up.
Topics: Adult; Appetite; Area Under Curve; Diet, Fat-Restricted; Energy Intake; Exercise; Fasting; Female; F | 2000 |
Bitter pills, bad medicine.
Topics: Anti-Obesity Agents; Drug Therapy, Combination; Fenfluramine; Humans; Liability, Legal; Obesity; Phe | 2001 |
The relationship between health-related quality of life and weight loss.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Drug Therapy, Com | 2001 |
Fenfluramine and phentermine.
Topics: Appetite Depressants; Drug Interactions; Drug Therapy, Combination; Fenfluramine; Obesity; Phentermi | 2001 |
Obesity: use of fenfluramine discussed at international symposium in Montreal.
Topics: Congresses as Topic; Fenfluramine; Humans; Obesity; Quebec | 1978 |
Three anorectic drugs: similar structures but different effects on brain and behavior.
Topics: Amphetamine; Animals; Appetite Depressants; Behavior; Blood Glucose; Body Weight; Brain; Dose-Respon | 1978 |
Therapeutic self-medication as a context for drug abuse research.
Topics: Adult; Body Weight; Dextroamphetamine; Drug Prescriptions; Female; Fenfluramine; Humans; Male; Metha | 1978 |
Some aspects of the physiological and pharmacological control of the synthesis of triacylglycerols and phospholipids.
Topics: Animals; Diabetes Mellitus; Energy Metabolism; Fenfluramine; Humans; Hypolipidemic Agents; Liver; Ob | 1978 |
Stress reverse the anorexia induced by amphetamine and methylphenidate but not fenfluramine.
Topics: Animals; Anorexia; Dextroamphetamine; Dose-Response Relationship, Drug; Feeding and Eating Disorders | 1978 |
Effects of prolonged fenfluramine administration in obese and nonobese mice.
Topics: Administration, Oral; Animals; Aurothioglucose; Blood Glucose; Body Composition; Body Weight; Female | 1977 |
Distribution of fenfluramine in normal and obese mice.
Topics: Adipose Tissue; Animals; Aurothioglucose; Brain; Female; Fenfluramine; Mice; Norfenfluramine; Obesit | 1978 |
[Is fenfluramine a suitable therapeutic principle in obese aged diabetics?].
Topics: Adult; Aged; Aging; Animals; Anorexia; Diabetes Complications; Fenfluramine; Humans; Lactates; Male; | 1979 |
[Is fenfluramine suitable as a therapeutic principle in obese aged diabetics? (end)].
Topics: Aged; Cholesterol; Diabetes Mellitus; Fenfluramine; Gastric Emptying; Glucose; Humans; Lactates; Obe | 1979 |
[Surgical reduction of the hypercellularity of adipose tissue in man. A premise to dietetic and drug therapy of obesity].
Topics: Abdomen; Adipose Tissue; Adult; Female; Fenfluramine; Humans; Lumbosacral Region; Middle Aged; Obesi | 1979 |
[New aspects in the management of overweight diabetics].
Topics: Diabetes Mellitus; Fenfluramine; Humans; Hypoglycemic Agents; Obesity | 1979 |
A three year follow-up of a behavioral treatment for obesity.
Topics: Behavior Therapy; Body Weight; Feeding Behavior; Female; Fenfluramine; Follow-Up Studies; Humans; Ma | 1979 |
Obesity--to treat or not to treat.
Topics: Adult; Appetite Depressants; Behavior Therapy; Diet, Reducing; Female; Fenfluramine; Humans; Intesti | 1979 |
Tissue ascorbic acid, fenfluramine, and changes in fat metabolism.
Topics: Animals; Ascorbic Acid; Ascorbic Acid Deficiency; Body Weight; Cholesterol; Disease Models, Animal; | 1979 |
The variable response to fenfluramine in obesity.
Topics: Adult; Body Weight; Female; Fenfluramine; Humans; Middle Aged; Obesity; Patient Compliance | 1979 |
Vitamin C and the anti-obesity effect of fenfluramine.
Topics: Animals; Appetite; Ascorbic Acid; Ascorbic Acid Deficiency; Body Weight; Female; Fenfluramine; Guine | 1979 |
Clinical trial of fenfluramine in the treatment of obesity in Thai people.
Topics: Adult; Body Weight; Female; Fenfluramine; Humans; Male; Middle Aged; Obesity; Thailand | 1977 |
[Diazoxide in the treatment of obesity].
Topics: Diazoxide; Dietary Proteins; Fenfluramine; Furosemide; Glucagon; Humans; Obesity; Triiodothyronine | 1977 |
The anorectic and hypotensive effect of fenfluramine in obesity.
Topics: Adolescent; Adult; Aged; Blood Pressure; Depression; Female; Fenfluramine; Humans; Male; Middle Aged | 1977 |
Eating in the laboratory: behavioural aspects of the positive energy balance.
Topics: Adult; Aged; Appetite; Child; Child, Preschool; Cues; Dementia; Eating; Energy Intake; Energy Metabo | 1977 |
[Drug therapy of obesity].
Topics: Appetite Depressants; Chorionic Gonadotropin; Diet, Reducing; Diuretics; Female; Fenfluramine; Human | 1978 |
Effect of anorexiant drugs on growth hormone secretion in obese children.
Topics: Adolescent; Anthropometry; Appetite Depressants; Arginine; Child; Diet; Female; Fenfluramine; Glucos | 1978 |
Behavioral treatment of obesity: the current status.
Topics: Behavior Therapy; Body Weight; Cues; Dietary Proteins; Eating; Energy Intake; Fasting; Feeding Behav | 1978 |
The effect of fenfluramine on obesity in rats--a new method for the screening of potential antiobesity agents [proceedings].
Topics: Animals; Diet; Drug Evaluation, Preclinical; Female; Fenfluramine; Obesity; Rats | 1978 |
Influence of fenfluramine on insulin and growth hormone secretion.
Topics: Adult; Blood Glucose; Fatty Acids, Nonesterified; Female; Fenfluramine; Glucose Tolerance Test; Grow | 1978 |
[Proceedings: Glucose tolerance insulin and lipids following 1 week of fenfluramine administration].
Topics: Body Weight; Fenfluramine; Glucose Tolerance Test; Humans; Insulin; Lipids; Obesity; Time Factors | 1975 |
Relative unresponsiveness of obese diabetic compared to obese non-diabetic subjects to the weight-reducing effect of fenfluramine.
Topics: Adult; Aged; Diabetes Mellitus; Female; Fenfluramine; Humans; Male; Middle Aged; Obesity | 1977 |
The effects of benfluramate on carbohydrate metabolism in obesity.
Topics: Adult; Blood Glucose; Body Weight; Carbohydrate Metabolism; Female; Fenfluramine; Humans; Kinetics; | 1977 |
[Therapy of obesity].
Topics: Adolescent; Adult; Alanine Transaminase; Appetite Depressants; Aspartate Aminotransferases; Body Wei | 1976 |
[The effect of fenfluramine on blood pressure and serum lipids of the obese].
Topics: Cholesterol; Fenfluramine; Humans; Obesity; Triglycerides | 1976 |
Effect of fenfluramine on overweight spayed bitches.
Topics: Animals; Castration; Dog Diseases; Dogs; Female; Fenfluramine; Hysterectomy; Obesity; Physical Exert | 1975 |
Fenfluramine in the treatment of hypertensive patients with refractory obesity.
Topics: Female; Fenfluramine; Humans; Hypertension; Male; Middle Aged; Obesity; Placebos; Pregnancy | 1975 |
[Treatment of obesity with fenfluramine].
Topics: Adult; Aged; Blood Pressure; Body Weight; Depression; Drug Evaluation; Female; Fenfluramine; Humans; | 1975 |
The effect of fenfluramine on disposition and rate of antipyrine elimination.
Topics: Adolescent; Adult; Animals; Antipyrine; Body Height; Body Weight; Female; Fenfluramine; Half-Life; H | 1975 |
A year's experience in a clinic for obese diabetics.
Topics: Adult; Aged; Body Weight; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diet, Reducin | 1975 |
[Pharmacotherapeutic possibilities in obesity].
Topics: Appetite Depressants; Biguanides; Carrageenan; Chorionic Gonadotropin; Fenfluramine; Glucose; Growth | 1975 |
A study of the energy and biochemical status of obese and non-obese students treated with 780SE.
Topics: Body Weight; Eating; Energy Metabolism; Fenfluramine; Humans; Lipids; Obesity | 1975 |
Assessment of new formulation of fenfluramine in the management of the obese, diabetic African.
Topics: Adult; Africa, Southern; Blood Pressure; Body Weight; Delayed-Action Preparations; Diabetes Mellitus | 1975 |
Fenfluramine withdrawal and epilepsy.
Topics: Adolescent; Adult; Aged; Electroencephalography; Epilepsy; Female; Fenfluramine; Humans; Middle Aged | 1975 |
The use of fenfluramine in patients undergoing therapeutic starvation.
Topics: Fenfluramine; Humans; Obesity; Starvation | 1975 |
Pharmacological effects of 780SE (992) on hyperlipidaemic and obese rats.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Fatty Acids, Nonesterified; Female; Fenfluram | 1975 |
[Glucose tolerance, insulin and lipids in adipose patients following one week of fenfluramine administration].
Topics: Blood Glucose; Fenfluramine; Glucose Tolerance Test; Humans; Insulin; Lipids; Obesity; Time Factors | 1975 |
Fenfluramine-associated hypertension.
Topics: Adult; Blood Pressure; Female; Fenfluramine; Humans; Hypertension; Male; Middle Aged; Obesity; Time | 1975 |
Dietary and medical treatments of obesity: an evaluative review.
Topics: Amphetamines; Appetite Depressants; Behavior Therapy; Chorionic Gonadotropin; Diet, Reducing; Evalua | 1975 |
A review of obesity and its management in 263 cases.
Topics: Adolescent; Adult; Aged; Child; Diet, Reducing; Family Practice; Female; Fenfluramine; Furosemide; H | 1975 |
Endocrine and metabolic disease. Obesity.
Topics: Diet, Reducing; Fenfluramine; Humans; Ileum; Jejunum; Mazindol; Obesity; Phenethylamines; Physical E | 1976 |
[Treatment of extreme obesity in a case of Prader-Willi-Labhart-syndrome (author's transl)].
Topics: Adolescent; Carbohydrate Metabolism, Inborn Errors; Fenfluramine; Humans; Hyperplasia; Intellectual | 1976 |
[Experience with the drug therapy of obesity in orthopedics].
Topics: Adult; Female; Fenfluramine; Humans; Joint Diseases; Male; Middle Aged; Obesity | 1976 |
Serotoninergic receptor activation by dextrofenfluramine enhances the blunted pituitary-adrenal responsiveness to corticotropin-releasing hormone in obese subjects.
Topics: Adrenocorticotropic Hormone; Adult; Corticotropin-Releasing Hormone; Fenfluramine; Humans; Hydrocort | 1992 |
[Obesity: drugs].
Topics: Antidepressive Agents; Appetite Depressants; Dietary Fiber; Fenfluramine; Humans; Obesity; Thyroid H | 1992 |
Overweight and Dexfenfluramine: A Perspective for the 1990s. Proceedings of a symposium of the 3rd European Congress on Obesity. Nice, 1991.
Topics: Fenfluramine; Humans; Obesity | 1992 |
Diminished epinephrine excretion in genetically obese (ob/ob) mice and monosodium glutamate-treated rats.
Topics: Adrenal Medulla; Analysis of Variance; Animals; Catecholamines; Epinephrine; Female; Fenfluramine; H | 1992 |
Toxic internuclear ophthalmoplegia related to antiobesity treatment.
Topics: Adult; Diplopia; Female; Fenfluramine; Humans; Obesity; Ophthalmoplegia; Triiodothyronine | 1992 |
[Acute pancreatitis and dexfenfluramine (Isomeride): apropos of a case].
Topics: Acute Disease; Female; Fenfluramine; Humans; Middle Aged; Obesity; Pancreatitis | 1992 |
Effects of fenfluramine on the metabolism of calcium and phosphorus in the rat: fenfluramine effects on Ca and P metabolism.
Topics: Animals; Bone Density; Calcium; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fenf | 1992 |
Sustained decreases in weight and serum insulin, glucose, triacylglycerol and cholesterol in JCR:LA-corpulent rats treated with D-fenfluramine.
Topics: Adipose Tissue; Aging; Animals; Blood Glucose; Body Weight; Cholesterol; Corticosterone; Eating; Fat | 1992 |
[Efficacy and acceptability of dexfenfluramine in women consulting in gynecology. 336 overweight patients treated for 3 months].
Topics: Adult; Female; Fenfluramine; Genital Diseases, Female; Humans; Menopause; Middle Aged; Obesity; Prem | 1992 |
[Effects of ponderal on the state of carbohydrate metabolism and insulin secretion in type 2 diabetes mellitus].
Topics: Adult; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; | 1991 |
Blunted growth hormone (GH) responsiveness to GH-releasing hormone in obese patients: influence of prolonged administration of the serotoninergic drug fenfluramine.
Topics: Adult; Female; Fenfluramine; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Insulin; Insu | 1991 |
Decreased serum lipids, serum insulin and triacylglycerol synthesis in adipose tissue of JCR:LA-corpulent rats treated with benfluorex.
Topics: Adipose Tissue; Animals; Body Weight; Feeding Behavior; Female; Fenfluramine; Glucose; Hormones; Hyp | 1991 |
[Judicious use of anorectics].
Topics: Appetite Depressants; Combined Modality Therapy; Counseling; Diet, Reducing; Fenfluramine; Humans; I | 1991 |
Effect of fenfluramine on prolactin and thyroid-stimulating-hormone response to thyrotropin-releasing-hormone in obese and normal women.
Topics: Adult; Female; Fenfluramine; Humans; Middle Aged; Obesity; Prolactin; Thyrotropin; Thyrotropin-Relea | 1990 |
[Dexfenfluramine: a new approach in the treatment of overweight].
Topics: Animals; Appetite Regulation; Fenfluramine; Humans; Obesity; Rats | 1990 |
Long-term actions of d-fenfluramine in two rat models of obesity. II. Responses to stress.
Topics: Animals; Body Weight; Brain Chemistry; Cold Temperature; Corticosterone; Female; Fenfluramine; Obesi | 1990 |
Pulmonary hypertension and fenfluramine.
Topics: Female; Fenfluramine; Heart Failure; Humans; Hypertension, Pulmonary; Middle Aged; Obesity | 1990 |
Effect of dexfenfluramine on gastric emptying of a mixed solid-liquid meal in obese subjects.
Topics: Adolescent; Adult; Body Weight; Female; Fenfluramine; Food; Gastric Emptying; Humans; Male; Middle A | 1990 |
Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system.
Topics: Adolescent; Adult; Female; Fenfluramine; Humans; Hypoglycemia; Insulin; Middle Aged; Obesity; Piperi | 1989 |
Long term actions of d-fenfluramine in two rat models of obesity. I Sustained reductions in body weight and adiposity without depletion of brain serotonin.
Topics: Adipose Tissue; Animals; Brain Chemistry; Energy Intake; Female; Fenfluramine; Lipid Metabolism; Lip | 1989 |
Fenfluramine studies.
Topics: Animals; Fenfluramine; Humans; Obesity; Rats | 1989 |
Possible involvement of a hypothalamic dopaminergic receptor in development of genetic obesity in mice.
Topics: Adenylyl Cyclases; Amphetamines; Animals; Ascorbic Acid; Aurothioglucose; Catechols; Diabetes Mellit | 1986 |
Brain and nutrition. Dexfenfluramine weight control and regulation of eating patterns. Satellite symposium to the Collegium Internationale Neuro-Psychopharmacologicum, 15th C.I.N.P. congress. Puerto Rico, U.S.A., December 14-17, 1987. Proceedings.
Topics: Animals; Appetite; Body Weight; Fenfluramine; Humans; Obesity | 1988 |
On the mechanism of action of dexfenfluramine: effect on alliesthesia and appetite motivation in lean and obese subjects.
Topics: Appetite Regulation; Eating; Female; Fenfluramine; Humans; Obesity; Taste; Taste Threshold | 1988 |
[Psychiatric complications in the treatment of obesity using fenfluramine].
Topics: Adult; Aged; Female; Fenfluramine; Humans; Male; Middle Aged; Obesity; Psychoses, Substance-Induced | 1988 |
Disposition of D-fenfluramine in lean and obese rats.
Topics: Animals; Cytochrome P-450 Enzyme System; Female; Fenfluramine; Half-Life; Kinetics; Microsomes, Live | 1988 |
Effect of fenfluramine on growth hormone and prolactin secretion in obese subjects.
Topics: Adult; Arginine; Female; Fenfluramine; Growth Hormone; Humans; Kinetics; Middle Aged; Obesity; Prola | 1987 |
[Appetite depressants: do they carry any weight?].
Topics: Appetite Depressants; Diet, Reducing; Feeding Behavior; Fenfluramine; Humans; Mazindol; Obesity | 1987 |
Recent evidence from human studies linking central serotoninergic function with carbohydrate intake.
Topics: Appetite Regulation; Dietary Carbohydrates; Fenfluramine; Food Preferences; Humans; Mood Disorders; | 1987 |
Fenfluramine discrimination in obese and lean Zucker rats: serotonergic mediation of effect.
Topics: Animals; Discrimination Learning; Dose-Response Relationship, Drug; Female; Fenfluramine; Obesity; P | 1986 |
Effect of dexfenfluramine on body weight set-point: study in the rat with hoarding behaviour.
Topics: Animals; Appetite Depressants; Body Weight; Energy Metabolism; Feeding Behavior; Fenfluramine; Homeo | 1986 |
[Treatment of compulsive eating disorders in an autistic girl by combining behavior therapy and pharmacotherapy. Case report].
Topics: Adolescent; Autistic Disorder; Behavior Therapy; Combined Modality Therapy; Compulsive Behavior; Die | 1986 |
Body weight set point theory.
Topics: Amphetamines; Animals; Appetite; Body Weight; Energy Intake; Feeding Behavior; Fenfluramine; Homeost | 1985 |
Fenfluramine delays gastric emptying of solid food.
Topics: Adult; Female; Fenfluramine; Gastric Emptying; Humans; Male; Obesity | 1985 |
Effect of dopamine agonists and fenfluramine on discriminative behavior in obese and lean Zucker rats.
Topics: Amphetamine; Animals; Appetite Depressants; Cocaine; Conditioning, Operant; Dextroamphetamine; Discr | 1985 |
Long-term treatment with fenfluramine in obese subjects.
Topics: Adipose Tissue; Adolescent; Adult; Body Weight; Diet, Reducing; Female; Fenfluramine; Glucose Tolera | 1985 |
Action of fenfluramine.
Topics: Anorexia Nervosa; Body Weight; Fenfluramine; Humans; Male; Obesity | 1973 |
Fenfluramine in treatment of obesity.
Topics: Female; Fenfluramine; Humans; Menstruation; Obesity | 1973 |
Letter: Fenfluramine and dreaming.
Topics: Adult; Dreams; Fenfluramine; Humans; Obesity; Sleep, REM | 1974 |
Letter: Fenfluramine and psychosis.
Topics: Adult; Depression; Female; Fenfluramine; Humans; Obesity; Psychoses, Substance-Induced; Schizophreni | 1974 |
Letter: Treating the obese sportsman.
Topics: Adult; Female; Fenfluramine; Humans; Male; Obesity; Sports Medicine | 1974 |
Drugs in obesity.
Topics: Amphetamine; Appetite Depressants; Diet, Reducing; Diuretics; Ephedrine; Fenfluramine; Health Educat | 1974 |
Clinical and biochemical studies on obese subjects using fenfluramine.
Topics: Anorexia Nervosa; Blood Pressure; Diarrhea; Fatigue; Female; Fenfluramine; Glucose Tolerance Test; H | 1974 |
Proceedings: Fenfluramine-induced hypertension.
Topics: Female; Fenfluramine; Humans; Hypertension; Male; Obesity | 1974 |
[Rôle of anorectic agents and other drugs in treatment of obesity].
Topics: Amphetamine; Appetite Depressants; Diuretics; Drug Synergism; Fenfluramine; Humans; Obesity | 1972 |
No. 7 fenfluramine "Ponderax".
Topics: Administration, Oral; Amphetamine; Diarrhea; Diet, Reducing; Fenfluramine; Obesity | 1972 |
[Effects of fenfluramine, administered on short or long-term basis, on lipolysis of obese subjects].
Topics: Fenfluramine; Humans; Lipid Mobilization; Obesity | 1973 |
[Treatment of heavy obese by high doses of fenfluramine].
Topics: Administration, Oral; Female; Fenfluramine; Humans; Male; Obesity | 1973 |
[Effects and indications of fenfluramine in the treatment of obesity].
Topics: Adolescent; Adult; Female; Fenfluramine; Humans; Male; Middle Aged; Obesity | 1973 |
[Psychological factors in the etiology of obesity and in the long-term treatment of psychiatric obese].
Topics: Fenfluramine; Humans; Obesity; Psychology | 1973 |
Fenfluramine and haemolytic anaemia.
Topics: Anemia, Hemolytic; Female; Fenfluramine; Humans; Middle Aged; Obesity | 1973 |
[Fenfluramine in the treatment of obesity].
Topics: Adult; Aged; Female; Fenfluramine; Humans; Male; Middle Aged; Obesity | 1973 |
[Treatment of obesity with fenfluramine. Clinical experiences and biochemical correlations].
Topics: Fenfluramine; Humans; Obesity | 1973 |
[Treatment of the risk factor overweight].
Topics: Age Factors; Body Weight; Female; Fenfluramine; Humans; Male; Middle Aged; Obesity | 1973 |
Fenfluramine: Its use in obesity.
Topics: Fenfluramine; Obesity | 1973 |
Fenfluramine and growth hormone release.
Topics: Fenfluramine; Growth Hormone; Humans; Male; Obesity; Physical Exertion; Sleep; Time Factors | 1973 |
[Insulin secretion and hydrocarbon tolerance in essential obesity in women (influence of fenfluramine, phenformin and D-amphetamine)].
Topics: Administration, Oral; Blood Glucose; Body Weight; Dextroamphetamine; Evaluation Studies as Topic; Fe | 1973 |
Fenfluramine and growth hormone release.
Topics: Adolescent; Female; Fenfluramine; Growth Hormone; Humans; Obesity; Secretory Rate | 1973 |
[Research and experience with fenfluramine in obesity].
Topics: Animals; Cholesterol; Diethylpropion; Fatty Acids, Nonesterified; Feeding Behavior; Fenfluramine; Hu | 1973 |
Fenfluramine and pigmented skin.
Topics: Fenfluramine; Humans; Obesity; Pigmentation; Pigmentation Disorders | 1973 |
[Reducing therapy in obesity].
Topics: Adolescent; Adult; Aged; Female; Fenfluramine; Humans; Male; Middle Aged; Obesity; Tablets | 1973 |
[Therapy of the risk-factor overweight in orthopedics].
Topics: Adult; Female; Fenfluramine; Humans; Joint Diseases; Joint Prosthesis; Male; Middle Aged; Obesity; S | 1973 |
[Drug therapy of obesity].
Topics: Diarrhea; Fatigue; Fenfluramine; Humans; Obesity | 1973 |
[Critical reflections on the concept "drug advertising" regarding the marketing of the drug Ponderal (fenfluramine)].
Topics: Advertising; Documentation; Drug Evaluation; Drug Industry; Ethics, Pharmacy; Fenfluramine; Humans; | 1973 |
Letter: Fenfluramine.
Topics: Chronic Disease; Fenfluramine; Humans; Obesity; Psoriasis | 1973 |
Medical treatment of obesity.
Topics: Amphetamine; Diet Therapy; Exercise Therapy; Fasting; Fenfluramine; Humans; Obesity | 1973 |
Letter: Fenfluramine approved by F.D.A. in America.
Topics: Fenfluramine; Humans; Obesity; United States; United States Food and Drug Administration | 1974 |
[Influence of fenfluramine on the weekly curve of weight loss during obesity].
Topics: Adolescent; Adult; Body Weight; Diet, Reducing; Drug Evaluation; Female; Fenfluramine; Humans; Middl | 1974 |
Letter: Fenfluramine in complicated obesity.
Topics: Diabetes Complications; Diabetes Mellitus; Female; Fenfluramine; Humans; Hypertension; Male; Middle | 1974 |
[Comparative action of fenfluramine and amphetamine in rats with hypothalamic obesity].
Topics: Amphetamine; Animal Nutritional Physiological Phenomena; Animals; Appetite Depressants; Body Weight; | 1969 |
Fenfluramine and pigmented naevi.
Topics: Female; Fenfluramine; Humans; Male; Nevus, Pigmented; Obesity | 1972 |
Anti-obesity action of fenfluramine.
Topics: Carbohydrate Metabolism; Fenfluramine; Humans; Hypothalamus; Lipid Metabolism; Obesity | 1972 |
Depression following fenfluramine withdrawal.
Topics: Adult; Depression; Female; Fenfluramine; Humans; Middle Aged; Obesity; Substance Withdrawal Syndrome | 1972 |
Effect of fenfluramine and dexamphetamine on pyruvate kinase.
Topics: Animals; Dextroamphetamine; Enzyme Activation; Fenfluramine; In Vitro Techniques; Magnesium; Muscles | 1971 |
To the Editor: Fenfluramine (Poderax) for obesity.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Child; Female; Fenfluramine; Fluorine; Humans; Male; | 1969 |
Fenfluramine in obesity.
Topics: Appetite Depressants; Female; Fenfluramine; Fluorine; Humans; Male; Obesity; Phenethylamines | 1970 |
Drugs for obesity.
Topics: Appetite Depressants; Fenfluramine; Fluorine; Obesity; Phenethylamines | 1970 |
Side-effects of fenfluramine.
Topics: Appetite Depressants; Fenfluramine; Fluorine; Humans; Obesity; Phenethylamines | 1970 |
A treatment for refractory obesity using fenfluramine without dietary restriction.
Topics: Adult; Appetite Depressants; Female; Fenfluramine; Fluorine; Humans; Male; Middle Aged; Obesity; Phe | 1970 |
Fenfluramine dependence.
Topics: Adult; Appetite Depressants; Depression; Female; Fenfluramine; Fluorine; Humans; Obesity; Phenethyla | 1971 |
Fenfluramine and dreaming.
Topics: Appetite Depressants; Dreams; Female; Fenfluramine; Fluorine; Humans; Obesity; Phenethylamines | 1971 |
The treatment of obesity.
Topics: Adipose Tissue; Amphetamine; Appetite Depressants; Chorionic Gonadotropin; Diet Fads; Diet, Reducing | 1971 |
Fenfluramine in obesity.
Topics: Appetite Depressants; Fenfluramine; Fluorine; Humans; Obesity; Phenethylamines | 1968 |
Comparative study of anorectic activity of d-amphetamine, chlorphentermine and fenfluramine in aurothioglucose obese and non-obese mice.
Topics: Animals; Appetite; Appetite Depressants; Chlorphentermine; Dextroamphetamine; Fenfluramine; Fluorine | 1968 |
Fenfluramine in the treatment of obesity.
Topics: Adolescent; Adult; Appetite Depressants; Child; Fenfluramine; Fluorine; Humans; Obesity; Phenethylam | 1968 |
[Fenfluramine. Anorexigenic drug in obstetrical practice].
Topics: Adult; Animals; Appetite Depressants; Dogs; Female; Fenfluramine; Fluorine; Gestational Age; Humans; | 1969 |